ClinicalTrials.gg
Active, not recruitingNCT03602859FIRSTUpdated Dec 31, 2025Results posted

A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer

A Phase 3 interventional study of Niraparib and Dostarlimab (TSR-042) in Ovarian Neoplasms and Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma, sponsored by Tesaro, Inc.. Active, not recruiting at 182 sites in 19 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-31.

Sponsored by Tesaro, Inc. (part of GlaxoSmithKline) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,400
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 44 studies testing niraparib in Ovarian Neoplasms — 9 open to participants now, 14 under way, 2 of them phase 3. niraparib · Ovarian Neoplasms.

Enrollment
Largest of 44
1,400 · median 41
Started
2018
with 4 others
Phase 3
7 of 44
none open now
Primary completion
2024-10
later than 2 of 13 live
Registered
13th of 44
by date
Lead sponsor
11 of 44
Tesaro, Inc.

Among the 44 studies testing niraparib in Ovarian Neoplasms, this one has the largest enrollment, is one of 5 that started in 2018, is one of 7 in phase 3, reaches primary completion later than 2 of the 13 other live ones, and was the 13th registered.

Ovarian Neoplasms

3,387 studies on the registry are indexed under Ovarian Neoplasms; 792 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

9 of the 44 studies testing niraparib in Ovarian Neoplasms are open now, in 10 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About niraparib

niraparib: first FDA approval 2017 (ZEJULA), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 605 Ovarian Neoplasms studies recruiting now, 442 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies testing niraparib in Ovarian Neoplasms, or all of them as a file.
02

Study summary

Ovarian cancer is a heterogeneous disease, characterized by complex molecular and genetic changes. The high expression of vascular endothelial growth factor (VEGF) receptor, programmed death receptor ligands 1 (PD-L1) expression, and deoxyribonucleic acid (DNA) damage in ovarian tumors provide several targets for treatment and maintenance of disease response. Given the unmet medical need of participants with advanced or metastatic ovarian cancer, this study design will enable investigators to provide participants with current SOC for ovarian cancer for the duration of the study. This is a global, multicenter, randomized, double-blind, controlled Phase 3 study that will primarily compare the progression-free survival (PFS) for participants receiving dostarlimab with SOC chemotherapy +/- bevacizumab followed by niraparib and dostarlimab maintenance +/- bevacizumab versus participants receiving SOC with chemotherapy followed by niraparib maintenance. This comparison will be investigated in participants of newly diagnosed stage III or IV advanced non-mucinous epithelial ovarian cancer participants and also to compare PFS of all participants with Stage III or IV high-grade non-mucinous epithelial ovarian cancer treated with platinum-based combination therapy, dostarlimab (TSR-042), and niraparib to SOC platinum-based combination therapy. The currently recommended SOC therapy for the first line treatment of Stage III or IV ovarian cancer is the combination of paclitaxel and carboplatin, with or without concurrent and maintenance bevacizumab. Participants will receive SOC during the chemotherapy Run-In period (cycle 1) before randomization to study treatment (cycle 2). Concurrent bevacizumab use must be determined prior to randomization at cycle 2.

03

Conditions studied

  • Ovarian Neoplasms
  • Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma

Browse trials for

Keywords

  • FIRST
  • FIRST trial
  • Niraparib
  • Dostarlimab (TSR-042)
  • Ovarian cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must be female, >=18 years of age, able to understand the study procedures, and agree to participate in the study by providing written .
  • Participants with a confirmed diagnosis of high-grade nonmucinous epithelial ovarian (serous, endometrioid, clear cell, carcinosarcoma, and mixed pathologies), fallopian tube, or peritoneal cancer that is Stage III or IV according to the International Federation of Gynecology and Obstetrics (FIGO) or tumor, node and staging criteria.
  • All participants with Stage IV disease are eligible. This includes those with inoperable disease, those who undergo primary debulking surgery (PDS) (R0 or macroscopic disease), or those for whom chemotherapy (NACT) is planned.
  • Participants with Stage III are eligible if they meet protocol defined criteria.
  • Participants must provide a blood sample for circulating tumor deoxyribonucleic acid (ctDNA) homologous recombinant repair (HRR) testing at pre-screening or screening.
  • Participant must provide a minimum of 1 formalin-fixed paraffin embedded (FFPE) block slide at pre-screening or screening for , homologous recombinant deficiency (HRD) testing.
  • Participants of must have a negative serum or urine pregnancy test (beta human chorionic gonadotropin) within 3 days prior to receiving the first dose of study treatment.
  • Participants must be , free from menses for >1 year, surgically sterilized, or willing to use highly effective to prevent pregnancy or must agree to abstain from activities that could result in pregnancy throughout the study, starting with enrollment through 180 days after the last dose of study treatment.
  • Participants must have adequate organ function: (ANC) >=1500/micro liter (μL;) count >=100000/μL; >=9 grams per deciliter (g/dL); Serum creatinine \<=1.5 × (ULN) or calculated >=60 milliliters per minute (mL/min) using the Cockcroft-Gault equation; total \<=1.5 × ULN or direct bilirubin \<=1.5 × ULN; and ALT \<=2.5 × ULN unless liver metastases are present, in which case they must be \<=5 × ULN.
  • Participants must have an score of 0 or 1.
  • Participants must have normal blood pressure (BP) or adequately treated and controlled hypertension (systolic BP \<=140 millimeters of mercury (mmHg) and/or diastolic BP \<=90 mmHg).
  • Participants must agree to complete health related quality of life (HRQoL) questionnaires throughout the study.
  • Participants must be able to take oral medication.

Exclusion criteria

Exclusion Criteria:

  • Participant has mucinous, germ cell, transitional cell, or undifferentiated tumor.
  • Participant has low-grade or Grade 1 epithelial ovarian cancer.
  • Participant has not adequately recovered from prior major surgery.
  • Participant is pregnant or is expecting to conceive children while receiving study drug or for up to 180 days after the last dose of study drug. Participant is breastfeeding or is expecting to breastfeed within 30 days of receiving the final dose of study drug (women should not breastfeed or store breastmilk for use, during niraparib treatment and for 30 days after receiving the final dose of study treatment).
  • Participant has known active central nervous system , carcinomatous meningitis, or both.
  • Participant has cardiovascular disease.
  • Participant has a bowel obstruction by clinical symptoms or computed tomography (CT) scan, subocclusive mesenteric disease, abdominal or gastrointestinal fistula, gastrointestinal perforation, or intra-abdominal abscess.
  • Participant has any known history or current diagnosis of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML).
  • Participant has been diagnosed and/or treated with any therapy for invasive cancer \<5 years from study enrollment, completed chemotherapy and/or targeted therapy (example, trastuzumab) less than 3 years from enrollment, or completed adjuvant hormonal therapy less than 4 weeks from enrollment.
  • Participants with definitively treated non-invasive such as cervical carcinoma in situ, ductal carcinoma in situ, Grade 1 or 2, Stage I endometrial cancer, or non-melanomatous skin cancer are allowed.
  • Participant is at increased bleeding risk due to concurrent conditions (example, major injuries or major surgery within the past 28 days prior to start of study treatment and/or history of hemorrhagic stroke, , subarachnoid hemorrhage, or clinically significant hemorrhage within the past 3 months).
  • Participant is .
  • Participant has known active (example, hepatitis B surface antigen reactive) or (example, hepatitis C virus ribonucleic acid [qualitative] is detected).
  • Participant is considered a poor medical risk due to a serious, uncontrolled medical disorder, non-malignant systemic disease, or uncontrolled infection.
  • Participant has had therapy administered within 4 weeks or within a time interval less than at least 5 half-lives of the investigational agent, whichever is longer, prior to the first scheduled day of dosing in this study.
  • Participant has received a within 14 days of planned start of study therapy. Seasonal influenza vaccines that do not contain live viruses are allowed.
  • Participant has a known or uncontrolled to the components of paclitaxel, carboplatin, niraparib, bevacizumab, dostarlimab, or their .
  • Prior treatment for high-grade nonmucinous epithelial ovarian, fallopian tube, or peritoneal cancer (immunotherapy, anti-cancer therapy, radiation therapy).
  • Participant has an active disease that has required systemic treatment in the past 2 years. Replacement therapy is not considered a form of systemic therapy (example, thyroid hormone or insulin).
  • Participant has a diagnosis of immunodeficiency or is receiving systemic therapy or any other form of systemic immunosuppressive therapy within 7 days prior to the first dose of study treatment.
Terms in these criteria, in plain language(29)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
1,400 participants (actual)

Study arms

  • Placebo comparator
    Participants receiving SOC+placebo

    Participants in this arm will receive SOC (carboplatin+paclitaxel+/-bevacizumab) in cycle 1 (each cycle is of 21 days) followed by SOC with chemotherapy treatment with dostarlimab placebo from cycles 2 to 6 and maintenance treatment of +/-bevacizumab along with niraparib placebo and dostarlimab placebo

    Drug: Standard of care · Drug: Dostarlimab-Placebo · Drug: Niraparib-Placebo

  • Active comparator
    Participants receiving SOC+niraparib

    Participants in this arm will receive SOC in cycle 1 (each cycle is of 21 days) followed by SOC with chemotherapy treatment dostarlimab placebo from cycles 2 to 6 and maintenance treatment of +/- bevacizumab with niraparib and dostarlimab placebo

    Drug: Niraparib · Drug: Standard of care · Drug: Dostarlimab-Placebo

  • Experimental
    Participants receiving SOC+dostarlimab+niraparib

    Participants in this arm will receive SOC in cycle 1 (each cycle is of 21 days) followed by SOC with chemotherapy treatment dostarlimab, and maintenance treatment of +/-bevacizumab with niraparib and dostarlimab

    Drug: Niraparib · Drug: Dostarlimab (TSR-042) · Drug: Standard of care

Interventions

  • Participants will receive oral capsules of niraparib as a unit dosage strength of 100 milligrams (mg)

    Also known as: ZEJULA

  • Participants will receive 500 mg dostarlimab on day 1 every 3 weeks from cycle 2 to 6 followed by 1000mg of dostarlimab on day 1 every 6 weeks to continue up to 3 years in the absence of disease progression, unacceptable toxicity, participant withdrawal, or investigator decision

  • DrugStandard of care

    Participants will receive SOC that includes paclitaxel 175 milligrams per square meter (mg/m\^2) on day 1 every 21 days + carboplatin area under the curve (AUC) of 5 to 6 milligrams per milliliter per minute (mg/mL/min) on day 1 every 21 days +/- bevacizumab 7.5 milligrams per kilograms (mg/kg) every 21 days or 15 mg/kg every 21 days for a total of 15 months.

  • DrugDostarlimab-Placebo

    Participants will receive 500 mg of dostarlimab-placebo on day 1 every 3 weeks from cycle 2 to 6 followed by 1000 mg of dostarlimab-placebo on day 1 every 6 weeks to continue up to 3 years in the absence of disease progression, unacceptable toxicity, participant withdrawal, or investigator decision

  • DrugNiraparib-Placebo

    Participants will receive oral capsules of niraparib-placebo as a unit dosage strength of 100 mg.

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS)

    Progression Free Survival (PFS) is defined as the time from the date of randomization to the date of first documented progressive disease (PD) or death due to any cause, whichever occurs first by the Investigator assessment according to Response Evaluation Criteria in Solid Tumors Criteria (RECIST) version 1.1. Progressive Disease is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started (e.g. percent change from nadir, where nadir is defined as the smallest sum of diameters recorded since treatment start). In addition, the sum must have an absolute increase from nadir of 5 millimeter (mm).

    Time frame: Up to approximately 316 weeks

Secondary outcomes

  1. Overall Survival (OS)

    Overall Survival (OS) is defined as the time from the date of randomization to the date of death by any cause.

    Time frame: Up to approximately 316 weeks

  2. PFS Determined by Blinded Independent Central Review (BICR) Per RECIST v1.1 Criteria

    Progression Free Survival (PFS) is defined as the time from the date of randomization to the date of first documented progressive disease (PD) or death due to any cause, whichever occurs first determined by the BICR according to RECIST version 1.1. Progressive Disease was defined as at least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started (e.g. percent change from nadir, where nadir is defined as the smallest sum of diameters recorded since treatment start). In addition, the sum must have an absolute increase from nadir of 5mm.

    Time frame: Up to approximately 316 weeks

  3. Time to First Subsequent Therapy (TFST)

    Time to First Subsequent Therapy (TFST) is defined as the time from randomization until the start date of the first subsequent anticancer therapy or death by any cause, whichever occurs first. First subsequent anticancer therapy is defined as the earliest anticancer therapy on the follow-up anticancer therapy form.

    Time frame: Up to approximately 316 weeks

  4. Time to Second Subsequent Therapy (TSST)

    Time to Second Subsequent Therapy (TSST) is defined as the time from the date of randomization to the start date of the second subsequent anticancer therapy or death of any cause, whichever occurs first. Second subsequent anticancer therapy is defined as an anticancer therapy with a start date after the first subsequent anticancer therapy and a recorded PD on first subsequent anticancer therapy, as captured on the follow-up anticancer therapy eCRF form.

    Time frame: Up to approximately 316 weeks

  5. Time to Second Progression (PFS2)

    PFS2 is defined as the time from the date of randomization to the date of first Progressive Disease per Investigator's assessment after initiation of subsequent anticancer therapy or death due to any cause, whichever occurs first. Progressive Disease is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started (e.g. percent change from nadir, where nadir is defined as the smallest sum of diameters recorded since treatment start). In addition, the sum must have an absolute increase from nadir of 5 millimeter (mm).

    Time frame: Up to approximately 316 weeks

  6. Objective Response Rate (ORR)

    Objective Response Rate (ORR) is defined as the percentage of participants with measurable disease at baseline achieving a best overall response (BOR) of complete response (CR) or partial response (PR) by Investigator assessment per RECIST v1.1 criteria for participants with measurable disease at baseline. PR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. CR is defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<)10 mm.

    Time frame: Up to approximately 316 weeks

  7. Duration of Response (DOR)

    DOR is defined as the time from the first documented response (complete response (CR) OR partial response (PR) ) to the first documented disease progression per Investigator assessed RECIST v1.1 or death by any cause in participants with measurable disease at baseline who responded to treatment. PR was defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. CR was defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PD was defined as at least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started (e.g. percent change from nadir, where nadir is defined as the smallest sum of diameters recorded since treatment start). In addition, the sum must have an absolute increase from nadir of 5 mm.

    Time frame: Up to approximately 316 weeks

  8. Disease Control Rate (DCR)

    Disease Control Rate (DCR) is defined as the percentage of participants with measurable disease at baseline achieving a best overall response (BOR) of complete response (CR), partial response (PR) or stable disease (SD) by Investigator assessment per RECIST v1.1 criteria for participants with measurable disease at baseline. PR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. CR is defined as the disappearance of all target lesions. SD defined as any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<)10 mm.

    Time frame: Up to approximately 316 weeks

  9. Number of Participants With Treatment Emergent Positive Antidrug Antibodies (ADAs) of Dostarlimab

    Serum samples were collected for the analysis of Anti-drug antibody (ADAs) of dostarlimab.

    Time frame: Up to approximately 316 weeks

  10. Change From Baseline (CFB) for the Visual Analogue Score (VAS) and Health Utility Index (HUI) of European Quality of Life 5-Dimension 5-Level Scale (EQ-5D-5L) Questionnaire

    EQ-5D-5L is a standardized, participant-rated health outcomes questionnaire covering five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. For each of dimensions, participant self-assigned score: 1 (no problems); 2 (slight problems); 3 (moderate problems); 4 (severe problems); 5 (extreme problems). VAS is collected separately and recorded from 0 (Worst imaginable health state) to 100 (Best imaginable health state). HUI values summarize how good or bad each health state is on a scale of 1 (full health) to 0 (worse health/dead). High HUI value indicates a good HRQoL. Baseline is defined as the latest, non-missing collected value, excluding end of treatment, safety follow-up, long term follow-up visits records and unscheduled visits after end of treatment (EOT).

    Time frame: Day1 of Chemo Cycles 2(baseline), 4&6; Day1 of Maintenance Cycles 1,2,3,6,9,12,15,17,23,29,35,41,47,53,59,65,71,77,83,89; EOT visit up to a maximum of 63 months; LTFU visit up to a maximum of 69 months(including SFU visit up to a maximum of 61 months)

  11. Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)

    The EORTC QLQ-C30 includes 30-items with single and multi-item scales. These included five functional scales (physical functioning \[PF\], role functioning \[RF\], cognitive functioning \[CF\], emotional functioning \[EF\] and social functioning \[SF\]), three symptom scales (fatigue, pain and nausea/vomiting \[N/V\]), a global health status (GHS)/ Quality-of-Life (QoL) scale, and six single items (constipation, diarrhoea, insomnia, dyspnoea, appetite loss \[AL\] and financial difficulties \[FD\]). Response options are 1 to 4. Scores were averaged and transformed to 0 to 100, a high score for functional scales/ GHS/QoL represent better functioning ability or health-related quality-of-life (HRQoL), whereas a high score for symptom scales/ single items represent significant symptomatology.

    Time frame: Day1 of Chemo Cycles 2(baseline), 4&6; Day1 of Maintenance Cycles 1,2,3,6,9,12,15,17,23,29,35,41,47,53,59,65,71,77,83,89; EOT visit up to a maximum of 63 months; LTFU visit up to a maximum of 69 months(including SFU visit up to a maximum of 61 months)

  12. Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire

    The EORTC QLQ-OV28 supplements the QLQ-C30. It includes three functional scales (body image (BI), sexuality (S), attitude to disease/treatment(ATD)) and five symptom scales/items (abdominal/GI symptoms (AS), peripheral neuropathy (PN), hormonal/menopausal symptoms (MS), other chemotherapy side effects (CSE), and hair loss (HS)). Participants responded on a scale of 1-4 (1=not at all, 2=a little, 3=quite a bit, 4=very much). Higher scores represent better functioning (better quality of life). For functional scales: improved (worsened) is defined as \>=10 points increase (decrease) from baseline. For symptom scales: improved (worsened) is defined as \>=10 points decrease (increase) from baseline. Baseline is defined as the latest, non-missing collected value, excluding end of treatment, safety follow-up, long term follow-up visits records and unscheduled visits after end of treatment.

    Time frame: Day1 of Chemo Cycles 2(baseline), 4&6; Day1 of Maintenance Cycles 1,2,3,6,9,12,15,17,23,29,35,41,47,53,59,65,71,77,83,89; EOT visit up to a maximum of 63 months; LTFU visit up to a maximum of 69 months(including SFU visit up to a maximum of 61 months)

07

Results

Posted Dec 31, 2025

Participant flow

Chemotherapy Run-In Period (Cycle 1)
Participant flow — Chemotherapy Run-In Period (Cycle 1)
MilestoneAll Enrolled ParticipantsPaclitaxel + Carboplatin + Dostarlimab Pbo +/- Bev, Then Niraparib Pbo+Dostarlimab Pbo +/-Bev (Arm1)Paclitaxel + Carboplatin + Dostarlimab Pbo +/- Bev, Then Niraparib+Dostarlimab Pbo +/- Bev (Arm2)Paclitaxel + Carboplatin + Dostarlimab +/- Bev, Then Niraparib+Dostarlimab +/- Bev (Arm3)
Started1400000
Completed1321000
Not completed79000
Withdrew: Adverse event10000
Withdrew: Disease progression per clinical criteria by investigator2000
Withdrew: Risk to patient3000
Withdrew: Severe noncompliance to protocol6000
Withdrew: Withdrawal by subject10000
Withdrew: Death10000
Withdrew: Other27000
Withdrew: Missing1000
Withdrew: Randomized but not treated10000
Chemo Treatment Period (Cycle 2 to 6)
Participant flow — Chemo Treatment Period (Cycle 2 to 6)
MilestoneAll Enrolled ParticipantsPaclitaxel + Carboplatin + Dostarlimab Pbo +/- Bev, Then Niraparib Pbo+Dostarlimab Pbo +/-Bev (Arm1)Paclitaxel + Carboplatin + Dostarlimab Pbo +/- Bev, Then Niraparib+Dostarlimab Pbo +/- Bev (Arm2)Paclitaxel + Carboplatin + Dostarlimab +/- Bev, Then Niraparib+Dostarlimab +/- Bev (Arm3)
Started0159417745
Itt population0193385753
Completed0129371645
Not completed03046100
Withdrew: Investigator decision0153
Withdrew: Adverse event071125
Withdrew: Progression/clinical progression071415
Withdrew: Risk to patient0215
Withdrew: Severe noncompliance to protocol0228
Withdrew: Withdrawal by subject091129
Withdrew: Lost to follow-up0001
Withdrew: Death0115
Withdrew: Other0119
Maintenance Period (Cycle 7 to 89)
Participant flow — Maintenance Period (Cycle 7 to 89)
MilestoneAll Enrolled ParticipantsPaclitaxel + Carboplatin + Dostarlimab Pbo +/- Bev, Then Niraparib Pbo+Dostarlimab Pbo +/-Bev (Arm1)Paclitaxel + Carboplatin + Dostarlimab Pbo +/- Bev, Then Niraparib+Dostarlimab Pbo +/- Bev (Arm2)Paclitaxel + Carboplatin + Dostarlimab +/- Bev, Then Niraparib+Dostarlimab +/- Bev (Arm3)
Started0129371645
Completed054177
Not completed0124330568
Withdrew: Ongoing032342
Withdrew: Adverse event062491
Withdrew: Thrombocytopenia platelet count not returned to >=100000 cells/ul w/in0012
Withdrew: Progression/clinical progression083251356
Withdrew: Risk to patient0212
Withdrew: Severe noncompliance to protocol0335
Withdrew: Withdrawal by subject072248
Withdrew: Lost to follow-up0022
Withdrew: Death0017
Withdrew: Unblinded due to being randomized to arm 101800
Withdrew: Investigator decision0001
Withdrew: Other02212

Outcome measures

PrimaryProgression Free Survival (PFS)

Progression Free Survival (PFS) is defined as the time from the date of randomization to the date of first documented progressive disease (PD) or death due to any cause, whichever occurs first by the Investigator assessment according to Response Evaluation Criteria in Solid Tumors Criteria (RECIST) version 1.1. Progressive Disease is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started (e.g. percent change from nadir, where nadir is defined as the smallest sum of diameters recorded since treatment start). In addition, the sum must have an absolute increase from nadir of 5 millimeter (mm).

Time frame:
Up to approximately 316 weeks
Reported as:
Median · Months
Progression Free Survival (PFS)
MonthsPaclitaxel + Carboplatin + Dostarlimab Pbo +/- Bev, Then Niraparib+Dostarlimab Pbo +/- Bev (Arm2)Paclitaxel + Carboplatin + Dostarlimab +/- Bev, Then Niraparib+Dostarlimab +/- Bev (Arm3)
Progression Free Survival (PFS)19.19 (16.59 to 20.99)20.63 (19.22 to 22.77)
Statistical analysis
  • Paclitaxel + Carboplatin + Dostarlimab Pbo +/- Bev, Then Niraparib+Dostarlimab Pbo +/- Bev (Arm2) vs Paclitaxel + Carboplatin + Dostarlimab +/- Bev, Then Niraparib+Dostarlimab +/- Bev (Arm3) · Stratified log-rank test · p = 0.0351 · Hazard ratio (hr): 0.85 · 95% CI 0.73 to 0.99Hazard ratio and p-value from the stratified Cox proportional hazards model and log-rank test (2-sided) are adjusted for the randomization stratification factors: concurrent bevacizumab use and homologous recombinant repair (HRR) mutation status.
SecondaryOverall Survival (OS)

Overall Survival (OS) is defined as the time from the date of randomization to the date of death by any cause.

Time frame:
Up to approximately 316 weeks
Reported as:
Median · Months
Overall Survival (OS)
MonthsPaclitaxel + Carboplatin + Dostarlimab Pbo +/- Bev, Then Niraparib+Dostarlimab Pbo +/- Bev (Arm2)Paclitaxel + Carboplatin + Dostarlimab +/- Bev, Then Niraparib+Dostarlimab +/- Bev (Arm3)
Overall Survival (OS)45.37 (40.28 to 52.21)44.39 (41.17 to 47.54)
SecondaryPFS Determined by Blinded Independent Central Review (BICR) Per RECIST v1.1 Criteria

Progression Free Survival (PFS) is defined as the time from the date of randomization to the date of first documented progressive disease (PD) or death due to any cause, whichever occurs first determined by the BICR according to RECIST version 1.1. Progressive Disease was defined as at least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started (e.g. percent change from nadir, where nadir is defined as the smallest sum of diameters recorded since treatment start). In addition, the sum must have an absolute increase from nadir of 5mm.

Time frame:
Up to approximately 316 weeks
Reported as:
Median · Months
PFS Determined by Blinded Independent Central Review (BICR) Per RECIST v1.1 Criteria
MonthsPaclitaxel + Carboplatin + Dostarlimab Pbo +/- Bev, Then Niraparib+Dostarlimab Pbo +/- Bev (Arm2)Paclitaxel + Carboplatin + Dostarlimab +/- Bev, Then Niraparib+Dostarlimab +/- Bev (Arm3)
PFS Determined by Blinded Independent Central Review (BICR) Per RECIST v1.1 Criteria23.56 (20.14 to 27.40)25.89 (23.36 to 32.49)
SecondaryTime to First Subsequent Therapy (TFST)

Time to First Subsequent Therapy (TFST) is defined as the time from randomization until the start date of the first subsequent anticancer therapy or death by any cause, whichever occurs first. First subsequent anticancer therapy is defined as the earliest anticancer therapy on the follow-up anticancer therapy form.

Time frame:
Up to approximately 316 weeks
Reported as:
Median · Months
Time to First Subsequent Therapy (TFST)
MonthsPaclitaxel + Carboplatin + Dostarlimab Pbo +/- Bev, Then Niraparib+Dostarlimab Pbo +/- Bev (Arm2)Paclitaxel + Carboplatin + Dostarlimab +/- Bev, Then Niraparib+Dostarlimab +/- Bev (Arm3)
Time to First Subsequent Therapy (TFST)20.93 (17.58 to 22.67)20.86 (19.15 to 23.92)
SecondaryTime to Second Subsequent Therapy (TSST)

Time to Second Subsequent Therapy (TSST) is defined as the time from the date of randomization to the start date of the second subsequent anticancer therapy or death of any cause, whichever occurs first. Second subsequent anticancer therapy is defined as an anticancer therapy with a start date after the first subsequent anticancer therapy and a recorded PD on first subsequent anticancer therapy, as captured on the follow-up anticancer therapy eCRF form.

Time frame:
Up to approximately 316 weeks
Reported as:
Median · Months
Time to Second Subsequent Therapy (TSST)
MonthsPaclitaxel + Carboplatin + Dostarlimab Pbo +/- Bev, Then Niraparib+Dostarlimab Pbo +/- Bev (Arm2)Paclitaxel + Carboplatin + Dostarlimab +/- Bev, Then Niraparib+Dostarlimab +/- Bev (Arm3)
Time to Second Subsequent Therapy (TSST)33.97 (30.06 to 37.49)35.32 (32.46 to 38.31)
SecondaryTime to Second Progression (PFS2)

PFS2 is defined as the time from the date of randomization to the date of first Progressive Disease per Investigator's assessment after initiation of subsequent anticancer therapy or death due to any cause, whichever occurs first. Progressive Disease is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started (e.g. percent change from nadir, where nadir is defined as the smallest sum of diameters recorded since treatment start). In addition, the sum must have an absolute increase from nadir of 5 millimeter (mm).

Time frame:
Up to approximately 316 weeks
Reported as:
Median · Months
Time to Second Progression (PFS2)
MonthsPaclitaxel + Carboplatin + Dostarlimab Pbo +/- Bev, Then Niraparib+Dostarlimab Pbo +/- Bev (Arm2)Paclitaxel + Carboplatin + Dostarlimab +/- Bev, Then Niraparib+Dostarlimab +/- Bev (Arm3)
Time to Second Progression (PFS2)31.84 (28.65 to 35.09)32.69 (30.42 to 35.38)
SecondaryObjective Response Rate (ORR)

Objective Response Rate (ORR) is defined as the percentage of participants with measurable disease at baseline achieving a best overall response (BOR) of complete response (CR) or partial response (PR) by Investigator assessment per RECIST v1.1 criteria for participants with measurable disease at baseline. PR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. CR is defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<)10 mm.

Time frame:
Up to approximately 316 weeks
Reported as:
Number · Percentage of participants
Objective Response Rate (ORR)
Percentage of participantsPaclitaxel + Carboplatin + Dostarlimab Pbo +/- Bev, Then Niraparib+Dostarlimab Pbo +/- Bev (Arm2)Paclitaxel + Carboplatin + Dostarlimab +/- Bev, Then Niraparib+Dostarlimab +/- Bev (Arm3)
Objective Response Rate (ORR)88 (83.7 to 91.6)88.4 (85.5 to 90.9)
SecondaryDuration of Response (DOR)

DOR is defined as the time from the first documented response (complete response (CR) OR partial response (PR) ) to the first documented disease progression per Investigator assessed RECIST v1.1 or death by any cause in participants with measurable disease at baseline who responded to treatment. PR was defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. CR was defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PD was defined as at least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started (e.g. percent change from nadir, where nadir is defined as the smallest sum of diameters recorded since treatment start). In addition, the sum must have an absolute increase from nadir of 5 mm.

Time frame:
Up to approximately 316 weeks
Reported as:
Median · Months
Duration of Response (DOR)
MonthsPaclitaxel + Carboplatin + Dostarlimab Pbo +/- Bev, Then Niraparib+Dostarlimab Pbo +/- Bev (Arm2)Paclitaxel + Carboplatin + Dostarlimab +/- Bev, Then Niraparib+Dostarlimab +/- Bev (Arm3)
Duration of Response (DOR)16.07 (13.86 to 18.40)18.27 (16.36 to 20.53)
SecondaryDisease Control Rate (DCR)

Disease Control Rate (DCR) is defined as the percentage of participants with measurable disease at baseline achieving a best overall response (BOR) of complete response (CR), partial response (PR) or stable disease (SD) by Investigator assessment per RECIST v1.1 criteria for participants with measurable disease at baseline. PR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. CR is defined as the disappearance of all target lesions. SD defined as any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<)10 mm.

Time frame:
Up to approximately 316 weeks
Reported as:
Number · Percentage of participants
Disease Control Rate (DCR)
Percentage of participantsPaclitaxel + Carboplatin + Dostarlimab Pbo +/- Bev, Then Niraparib+Dostarlimab Pbo +/- Bev (Arm2)Paclitaxel + Carboplatin + Dostarlimab +/- Bev, Then Niraparib+Dostarlimab +/- Bev (Arm3)
Disease Control Rate (DCR)93.7 (90.2 to 96.2)93.6 (91.2 to 95.5)
SecondaryNumber of Participants With Treatment Emergent Positive Antidrug Antibodies (ADAs) of Dostarlimab

Serum samples were collected for the analysis of Anti-drug antibody (ADAs) of dostarlimab.

Time frame:
Up to approximately 316 weeks
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Positive Antidrug Antibodies (ADAs) of Dostarlimab
ParticipantsPaclitaxel + Carboplatin + Dostarlimab +/- Bev, Then Niraparib+Dostarlimab +/- Bev (Arm3)
Number of Participants With Treatment Emergent Positive Antidrug Antibodies (ADAs) of Dostarlimab17
SecondaryChange From Baseline (CFB) for the Visual Analogue Score (VAS) and Health Utility Index (HUI) of European Quality of Life 5-Dimension 5-Level Scale (EQ-5D-5L) Questionnaire

EQ-5D-5L is a standardized, participant-rated health outcomes questionnaire covering five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. For each of dimensions, participant self-assigned score: 1 (no problems); 2 (slight problems); 3 (moderate problems); 4 (severe problems); 5 (extreme problems). VAS is collected separately and recorded from 0 (Worst imaginable health state) to 100 (Best imaginable health state). HUI values summarize how good or bad each health state is on a scale of 1 (full health) to 0 (worse health/dead). High HUI value indicates a good HRQoL. Baseline is defined as the latest, non-missing collected value, excluding end of treatment, safety follow-up, long term follow-up visits records and unscheduled visits after end of treatment (EOT).

Time frame:
Day1 of Chemo Cycles 2(baseline), 4&6; Day1 of Maintenance Cycles 1,2,3,6,9,12,15,17,23,29,35,41,47,53,59,65,71,77,83,89; EOT visit up to a maximum of 63 months; LTFU visit up to a maximum of 69 months(including SFU visit up to a maximum of 61 months)
Reported as:
Mean · Scores on a scale
Change From Baseline (CFB) for the Visual Analogue Score (VAS) and Health Utility Index (HUI) of European Quality of Life 5-Dimension 5-Level Scale (EQ-5D-5L) Questionnaire
Scores on a scalePaclitaxel + Carboplatin + Dostarlimab Pbo +/- Bev, Then Niraparib+Dostarlimab Pbo +/- Bev (Arm2)Paclitaxel + Carboplatin + Dostarlimab +/- Bev, Then Niraparib+Dostarlimab +/- Bev (Arm3)
EQ-VAS, Cycle 4 Chemotherapy1.2 ± 18.330.1 ± 18.00
EQ-VAS, Cycle 6 Chemotherapy4.6 ± 18.842.0 ± 18.69
EQ-VAS, Cycle 1 Maintenance5.9 ± 19.993.2 ± 18.25
EQ-VAS, Cycle 2 Maintenance6.9 ± 19.032.9 ± 19.52
EQ-VAS, Cycle 3 Maintenance4.9 ± 20.424.9 ± 19.32
EQ-VAS, Cycle 6 Maintenance5.1 ± 17.815.3 ± 18.80
EQ-VAS, Cycle 9 Maintenance7.6 ± 19.746.6 ± 18.09
EQ-VAS, Cycle 12 Maintenance9.6 ± 20.586.6 ± 17.59
EQ-VAS, Cycle 15 Maintenance8.1 ± 23.566.6 ± 17.72
EQ-VAS, Cycle 17 Maintenance14.8 ± 26.2911.5 ± 19.81
EQ-VAS, Cycle 23 Maintenance13.3 ± 22.9510.4 ± 20.89
EQ-VAS, Cycle 29 Maintenance12.5 ± 22.2710.3 ± 19.06
EQ-VAS, Cycle 35 Maintenance9.9 ± 19.0010.4 ± 16.55
EQ-VAS, Cycle 41 Maintenance9.8 ± 22.9110.1 ± 18.96
EQ-VAS, Cycle 47 Maintenance8.8 ± 21.1610.9 ± 18.39
EQ-VAS, Cycle 53 Maintenance8.5 ± 25.9411.4 ± 18.65
EQ-VAS, Cycle 59 Maintenance7.3 ± 25.1510.7 ± 18.14
EQ-VAS, Cycle 65 Maintenance2.5 ± 11.1014.9 ± 19.55
EQ-VAS, Cycle 71 Maintenance5.9 ± 10.7813.0 ± 17.09
EQ-VAS, Cycle 77 Maintenance9.3 ± 9.8415.9 ± 18.65
EQ-VAS, Cycle 83 Maintenance9.7 ± 6.3519.3 ± 21.45
EQ-VAS, Cycle 89 Maintenance—-5.0 ± NA
EQ-VAS, End of Treatment0.7 ± 21.93-0.1 ± 22.51
EQ-VAS, Safety Follow-up3.5 ± 21.89-0.1 ± 21.45
EQ-VAS, Long term Follow-up (LTFU) EOT + 3 months3.0 ± 21.472.7 ± 20.06
EQ-VAS, LTFU-EOT + 9 months1.1 ± 18.142.4 ± 21.53
EQ-VAS, LTFU-EOT + 15 months2.3 ± 21.574.3 ± 19.29
EQ-VAS, LTFU-EOT + 21 months1.8 ± 19.391.8 ± 24.79
EQ-VAS, LTFU-EOT + 27 months5.5 ± 15.875.0 ± 21.42
EQ-VAS, LTFU-EOT + 33 months4.6 ± 21.759.2 ± 17.02
EQ-VAS, LTFU-EOT + 39 months5.9 ± 22.38-1.9 ± 13.89
EQ-VAS, LTFU-EOT + 45 months5.5 ± 19.23-4.7 ± 16.00
EQ-VAS, LTFU-EOT + 51 months0.0 ± 0.03.6 ± 11.50
EQ-VAS, LTFU-EOT + 57 months2.5 ± 3.54-12.0 ± NA
EQ-VAS, LTFU-EOT + 63 months0.0 ± NA—
HUI, Cycle 4 Chemotherapy-0.0033 ± 0.16847-0.0035 ± 0.19281
HUI, Cycle 6 Chemotherapy-0.0049 ± 0.18207-0.0065 ± 0.19647
HUI, Cycle 1 Maintenance0.0034 ± 0.19324-0.0043 ± 0.20270
HUI, Cycle 2 Maintenance0.0118 ± 0.187810.0036 ± 0.20052
HUI, Cycle 3 Maintenance-0.0015 ± 0.21441-0.0073 ± 0.21785
HUI, Cycle 6 Maintenance0.0184 ± 0.217040.0029 ± 0.19389
HUI, Cycle 9 Maintenance0.0281 ± 0.190010.0181 ± 0.20597
HUI, Cycle 12 Maintenance0.0326 ± 0.213330.0177 ± 0.19577
HUI, Cycle 15 Maintenance0.0379 ± 0.210600.0136 ± 0.18809
HUI, Cycle 17 Maintenance0.0777 ± 0.236030.0545 ± 0.19913
HUI, Cycle 23 Maintenance0.0353 ± 0.165620.0012 ± 0.22021
HUI, Cycle 29 Maintenance0.0610 ± 0.232680.0058 ± 0.18551
HUI, Cycle 35 Maintenance0.0295 ± 0.209560.0175 ± 0.19186
HUI, Cycle 41 Maintenance0.0247 ± 0.239960.0084 ± 0.22003
HUI, Cycle 47 Maintenance0.0251 ± 0.204780.0263 ± 0.19109
HUI, Cycle 53 Maintenance0.0285 ± 0.17721-0.0270 ± 0.20412
HUI, Cycle 59 Maintenance0.0156 ± 0.11589-0.0210 ± 0.19579
HUI, Cycle 65 Maintenance0.0358 ± 0.10770-0.0302 ± 0.20843
HUI, Cycle 71 Maintenance0.0604 ± 0.089410.0165 ± 0.11503
HUI, Cycle 77 Maintenance0.0783 ± 0.060870.0193 ± 0.20537
HUI, Cycle 83 Maintenance0.0200 ± 0.099520.0720 ± 0.08398
HUI, Cycle 89 Maintenance—0.0640 ± 0.09051
HUI, End of Treatment-0.0251 ± 0.22757-0.0310 ± 0.24320
HUI, Safety Follow-up-0.0326 ± 0.22131-0.0460 ± 0.23927
HUI, LTFU- EOT + 3 months-0.0439 ± 0.22896-0.0222 ± 0.22768
HUI, LTFU-EOT + 9 months-0.0723 ± 0.20713-0.0400 ± 0.23756
HUI, LTFU-EOT + 15 months-0.0323 ± 0.20492-0.0386 ± 0.22117
HUI, LTFU-EOT + 21 months-0.0370 ± 0.16768-0.0457 ± 0.26270
HUI, LTFU-EOT + 27 months-0.0407 ± 0.17664-0.0635 ± 0.23835
HUI, LTFU-EOT + 33 months-0.0547 ± 0.15663-0.0114 ± 0.23974
HUI, LTFU-EOT + 39 months-0.0374 ± 0.11831-0.0993 ± 0.24071
HUI, LTFU-EOT + 45 months-0.0568 ± 0.14026-0.0648 ± 0.23505
HUI, LTFU-EOT + 51 months0.0000 ± NA0.0028 ± 0.18532
HUI, LTFU-EOT + 57 months-0.0780 ± 0.110310.0000 ± NA
HUI, LTFU-EOT + 63 months0.0000 ± NA—
SecondaryNumber of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)

The EORTC QLQ-C30 includes 30-items with single and multi-item scales. These included five functional scales (physical functioning \[PF\], role functioning \[RF\], cognitive functioning \[CF\], emotional functioning \[EF\] and social functioning \[SF\]), three symptom scales (fatigue, pain and nausea/vomiting \[N/V\]), a global health status (GHS)/ Quality-of-Life (QoL) scale, and six single items (constipation, diarrhoea, insomnia, dyspnoea, appetite loss \[AL\] and financial difficulties \[FD\]). Response options are 1 to 4. Scores were averaged and transformed to 0 to 100, a high score for functional scales/ GHS/QoL represent better functioning ability or health-related quality-of-life (HRQoL), whereas a high score for symptom scales/ single items represent significant symptomatology.

Time frame:
Day1 of Chemo Cycles 2(baseline), 4&6; Day1 of Maintenance Cycles 1,2,3,6,9,12,15,17,23,29,35,41,47,53,59,65,71,77,83,89; EOT visit up to a maximum of 63 months; LTFU visit up to a maximum of 69 months(including SFU visit up to a maximum of 61 months)
Reported as:
Count of participants · Participants
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
ParticipantsPaclitaxel + Carboplatin + Dostarlimab Pbo +/- Bev, Then Niraparib+Dostarlimab Pbo +/- Bev (Arm2)Paclitaxel + Carboplatin + Dostarlimab +/- Bev, Then Niraparib+Dostarlimab +/- Bev (Arm3)
GHS/QoL, Cycle 4 Chemotherapy — Worsened70148
GHS/QoL, Cycle 4 Chemotherapy — Stable142283
GHS/QoL, Cycle 4 Chemotherapy — Improved71116
PF, Cycle 4 Chemotherapy — Worsened77150
PF, Cycle 4 Chemotherapy — Stable146290
PF, Cycle 4 Chemotherapy — Improved60108
RF, Cycle 4 Chemotherapy — Worsened95183
RF, Cycle 4 Chemotherapy — Stable104207
RF, Cycle 4 Chemotherapy — Improved84157
EF, Cycle 4 Chemotherapy — Worsened46128
EF, Cycle 4 Chemotherapy — Stable179317
EF, Cycle 4 Chemotherapy — Improved58103
CF, Cycle 4 Chemotherapy — Worsened93174
CF, Cycle 4 Chemotherapy — Stable149272
CF, Cycle 4 Chemotherapy — Improved41102
SF, Cycle 4 Chemotherapy — Worsened95201
SF, Cycle 4 Chemotherapy — Stable120220
SF, Cycle 4 Chemotherapy — Improved67127
Fatigue, Cycle 4 Chemotherapy — Worsened121223
Fatigue, Cycle 4 Chemotherapy — Stable79155
Fatigue, Cycle 4 Chemotherapy — Improved83170
N/V, Cycle 4 Chemotherapy — Worsened4791
N/V, Cycle 4 Chemotherapy — Stable191363
N/V, Cycle 4 Chemotherapy — Improved4594
Pain, Cycle 4 Chemotherapy — Worsened88170
Pain, Cycle 4 Chemotherapy — Stable107224
Pain, Cycle 4 Chemotherapy — Improved88154
Dyspnoea, Cycle 4 Chemotherapy — Worsened59103
Dyspnoea, Cycle 4 Chemotherapy — Stable179346
Dyspnoea, Cycle 4 Chemotherapy — Improved4599
Insomnia, Cycle 4 Chemotherapy — Worsened5896
Insomnia, Cycle 4 Chemotherapy — Stable147319
Insomnia, Cycle 4 Chemotherapy — Improved78133
AL, Cycle 4 Chemotherapy — Worsened53111
AL, Cycle 4 Chemotherapy — Stable163322
AL, Cycle 4 Chemotherapy — Improved67115
Constipation, Cycle 4 Chemotherapy — Worsened67104
Constipation, Cycle 4 Chemotherapy — Stable153299
Constipation, Cycle 4 Chemotherapy — Improved63145
Diarrhoea, Cycle 4 Chemotherapy — Worsened4182
Diarrhoea, Cycle 4 Chemotherapy — Stable196373
Diarrhoea, Cycle 4 Chemotherapy — Improved4693
FD, Cycle 4 Chemotherapy — Worsened2898
FD, Cycle 4 Chemotherapy — Stable214380
FD, Cycle 4 Chemotherapy — Improved4168
GHS/QoL, Cycle 6 Chemotherapy — Worsened66147
GHS/QoL, Cycle 6 Chemotherapy — Stable133260
GHS/QoL, Cycle 6 Chemotherapy — Improved74147
PF, Cycle 6 Chemotherapy — Worsened80163
PF, Cycle 6 Chemotherapy — Stable131274
PF, Cycle 6 Chemotherapy — Improved62117
RF, Cycle 6 Chemotherapy — Worsened78195
RF, Cycle 6 Chemotherapy — Stable104189
RF, Cycle 6 Chemotherapy — Improved91169
EF, Cycle 6 Chemotherapy — Worsened48123
EF, Cycle 6 Chemotherapy — Stable162316
EF, Cycle 6 Chemotherapy — Improved63114
CF, Cycle 6 Chemotherapy — Worsened92199
CF, Cycle 6 Chemotherapy — Stable144260
CF, Cycle 6 Chemotherapy — Improved3794
SF, Cycle 6 Chemotherapy — Worsened79185
SF, Cycle 6 Chemotherapy — Stable116222
SF, Cycle 6 Chemotherapy — Improved78146
Fatigue, Cycle 6 Chemotherapy — Worsened110221
Fatigue, Cycle 6 Chemotherapy — Stable71163
Fatigue, Cycle 6 Chemotherapy — Improved92170
N/V, Cycle 6 Chemotherapy — Worsened43116
N/V, Cycle 6 Chemotherapy — Stable182340
N/V, Cycle 6 Chemotherapy — Improved4898
Pain, Cycle 6 Chemotherapy — Worsened76150
Pain, Cycle 6 Chemotherapy — Stable99220
Pain, Cycle 6 Chemotherapy — Improved98184
Dyspnoea, Cycle 6 Chemotherapy — Worsened56150
Dyspnoea, Cycle 6 Chemotherapy — Stable174316
Dyspnoea, Cycle 6 Chemotherapy — Improved4387
Insomnia, Cycle 6 Chemotherapy — Worsened54110
Insomnia, Cycle 6 Chemotherapy — Stable135301
Insomnia, Cycle 6 Chemotherapy — Improved84142
AL, Cycle 6 Chemotherapy — Worsened44113
AL, Cycle 6 Chemotherapy — Stable162288
AL, Cycle 6 Chemotherapy — Improved67153
Constipation, Cycle 6 Chemotherapy — Worsened51117
Constipation, Cycle 6 Chemotherapy — Stable148300
Constipation, Cycle 6 Chemotherapy — Improved73136
Diarrhoea, Cycle 6 Chemotherapy — Worsened3478
Diarrhoea, Cycle 6 Chemotherapy — Stable193388
Diarrhoea, Cycle 6 Chemotherapy — Improved4688
FD, Cycle 6 Chemotherapy — Worsened3591
FD, Cycle 6 Chemotherapy — Stable203395
FD, Cycle 6 Chemotherapy — Improved3566
GHS/QoL, Cycle 1 Maintenance — Worsened50135
GHS/QoL, Cycle 1 Maintenance — Stable138241
GHS/QoL, Cycle 1 Maintenance — Improved78126
PF, Cycle 1 Maintenance — Worsened62130
PF, Cycle 1 Maintenance — Stable127255
PF, Cycle 1 Maintenance — Improved76119
RF, Cycle 1 Maintenance — Worsened73144
RF, Cycle 1 Maintenance — Stable100186
RF, Cycle 1 Maintenance — Improved93172
EF, Cycle 1 Maintenance — Worsened55127
EF, Cycle 1 Maintenance — Stable150283
EF, Cycle 1 Maintenance — Improved6194
CF, Cycle 1 Maintenance — Worsened96181
CF, Cycle 1 Maintenance — Stable132246
CF, Cycle 1 Maintenance — Improved3877
SF, Cycle 1 Maintenance — Worsened83154
SF, Cycle 1 Maintenance — Stable109224
SF, Cycle 1 Maintenance — Improved74126
Fatigue, Cycle 1 Maintenance — Worsened89180
Fatigue, Cycle 1 Maintenance — Stable71145
Fatigue, Cycle 1 Maintenance — Improved106179
N/V, Cycle 1 Maintenance — Worsened3590
N/V, Cycle 1 Maintenance — Stable178317
N/V, Cycle 1 Maintenance — Improved5397
Pain, Cycle 1 Maintenance — Worsened58127
Pain, Cycle 1 Maintenance — Stable104186
Pain, Cycle 1 Maintenance — Improved104191
Dyspnoea, Cycle 1 Maintenance — Worsened64109
Dyspnoea, Cycle 1 Maintenance — Stable159297
Dyspnoea, Cycle 1 Maintenance — Improved4395
Insomnia, Cycle 1 Maintenance — Worsened4998
Insomnia, Cycle 1 Maintenance — Stable143253
Insomnia, Cycle 1 Maintenance — Improved74153
AL, Cycle 1 Maintenance — Worsened4086
AL, Cycle 1 Maintenance — Stable154285
AL, Cycle 1 Maintenance — Improved72132
Constipation, Cycle 1 Maintenance — Worsened5488
Constipation, Cycle 1 Maintenance — Stable143270
Constipation, Cycle 1 Maintenance — Improved68145
Diarrhoea, Cycle 1 Maintenance — Worsened2887
Diarrhoea, Cycle 1 Maintenance — Stable189338
Diarrhoea, Cycle 1 Maintenance — Improved4976
FD, Cycle 1 Maintenance — Worsened3374
FD, Cycle 1 Maintenance — Stable195361
FD, Cycle 1 Maintenance — Improved3868
GHS/QoL, Cycle 2 Maintenance — Worsened47118
GHS/QoL, Cycle 2 Maintenance — Stable110211
GHS/QoL, Cycle 2 Maintenance — Improved74117
PF, Cycle 2 Maintenance — Worsened43107
PF, Cycle 2 Maintenance — Stable115236
PF, Cycle 2 Maintenance — Improved72103
RF, Cycle 2 Maintenance — Worsened58139
RF, Cycle 2 Maintenance — Stable83151
RF, Cycle 2 Maintenance — Improved89155
EF, Cycle 2 Maintenance — Worsened37103
EF, Cycle 2 Maintenance — Stable134253
EF, Cycle 2 Maintenance — Improved6090
CF, Cycle 2 Maintenance — Worsened78160
CF, Cycle 2 Maintenance — Stable117208
CF, Cycle 2 Maintenance — Improved3678
SF, Cycle 2 Maintenance — Worsened63137
SF, Cycle 2 Maintenance — Stable91177
SF, Cycle 2 Maintenance — Improved77132
Fatigue, Cycle 2 Maintenance — Worsened55146
Fatigue, Cycle 2 Maintenance — Stable68138
Fatigue, Cycle 2 Maintenance — Improved108161
N/V, Cycle 2 Maintenance — Worsened4294
N/V, Cycle 2 Maintenance — Stable144266
N/V, Cycle 2 Maintenance — Improved4585
Pain, Cycle 2 Maintenance — Worsened48128
Pain, Cycle 2 Maintenance — Stable88159
Pain, Cycle 2 Maintenance — Improved95159
Dyspnoea, Cycle 2 Maintenance — Worsened3491
Dyspnoea, Cycle 2 Maintenance — Stable155277
Dyspnoea, Cycle 2 Maintenance — Improved4177
Insomnia, Cycle 2 Maintenance — Worsened4190
Insomnia, Cycle 2 Maintenance — Stable115220
Insomnia, Cycle 2 Maintenance — Improved75135
AL, Cycle 2 Maintenance — Worsened2990
AL, Cycle 2 Maintenance — Stable134250
AL, Cycle 2 Maintenance — Improved67105
Constipation, Cycle 2 Maintenance — Worsened4285
Constipation, Cycle 2 Maintenance — Stable118249
Constipation, Cycle 2 Maintenance — Improved71110
Diarrhoea, Cycle 2 Maintenance — Worsened2252
Diarrhoea, Cycle 2 Maintenance — Stable160315
Diarrhoea, Cycle 2 Maintenance — Improved4979
FD, Cycle 2 Maintenance — Worsened2671
FD, Cycle 2 Maintenance — Stable175316
FD, Cycle 2 Maintenance — Improved3059
GHS/QoL, Cycle 3 Maintenance — Worsened56146
GHS/QoL, Cycle 3 Maintenance — Stable110199
GHS/QoL, Cycle 3 Maintenance — Improved76112
PF, Cycle 3 Maintenance — Worsened49130
PF, Cycle 3 Maintenance — Stable113216
PF, Cycle 3 Maintenance — Improved79109
RF, Cycle 3 Maintenance — Worsened68146
RF, Cycle 3 Maintenance — Stable85163
RF, Cycle 3 Maintenance — Improved88147
EF, Cycle 3 Maintenance — Worsened60122
EF, Cycle 3 Maintenance — Stable126255
EF, Cycle 3 Maintenance — Improved5680
CF, Cycle 3 Maintenance — Worsened83183
CF, Cycle 3 Maintenance — Stable120193
CF, Cycle 3 Maintenance — Improved3981
SF, Cycle 3 Maintenance — Worsened63152
SF, Cycle 3 Maintenance — Stable101185
SF, Cycle 3 Maintenance — Improved78119
Fatigue, Cycle 3 Maintenance — Worsened84182
Fatigue, Cycle 3 Maintenance — Stable51119
Fatigue, Cycle 3 Maintenance — Improved106156
N/V, Cycle 3 Maintenance — Worsened70147
N/V, Cycle 3 Maintenance — Stable122241
N/V, Cycle 3 Maintenance — Improved4968
Pain, Cycle 3 Maintenance — Worsened58133
Pain, Cycle 3 Maintenance — Stable95167
Pain, Cycle 3 Maintenance — Improved89157
Dyspnoea, Cycle 3 Maintenance — Worsened65121
Dyspnoea, Cycle 3 Maintenance — Stable136258
Dyspnoea, Cycle 3 Maintenance — Improved3977
Insomnia, Cycle 3 Maintenance — Worsened55115
Insomnia, Cycle 3 Maintenance — Stable117221
Insomnia, Cycle 3 Maintenance — Improved69121
AL, Cycle 3 Maintenance — Worsened45124
AL, Cycle 3 Maintenance — Stable129229
AL, Cycle 3 Maintenance — Improved66104
Constipation, Cycle 3 Maintenance — Worsened73125
Constipation, Cycle 3 Maintenance — Stable110221
Constipation, Cycle 3 Maintenance — Improved58111
Diarrhoea, Cycle 3 Maintenance — Worsened1538
Diarrhoea, Cycle 3 Maintenance — Stable177329
Diarrhoea, Cycle 3 Maintenance — Improved5090
FD, Cycle 3 Maintenance — Worsened3168
FD, Cycle 3 Maintenance — Stable171327
FD, Cycle 3 Maintenance — Improved4060
GHS/QoL, Cycle 6 Maintenance — Worsened3089
GHS/QoL, Cycle 6 Maintenance — Stable101192
GHS/QoL, Cycle 6 Maintenance — Improved70129
PF, Cycle 6 Maintenance — Worsened3986
PF, Cycle 6 Maintenance — Stable96222
PF, Cycle 6 Maintenance — Improved65101
RF, Cycle 6 Maintenance — Worsened52100
RF, Cycle 6 Maintenance — Stable75171
RF, Cycle 6 Maintenance — Improved74139
EF, Cycle 6 Maintenance — Worsened3686
EF, Cycle 6 Maintenance — Stable113246
EF, Cycle 6 Maintenance — Improved5278
CF, Cycle 6 Maintenance — Worsened68134
CF, Cycle 6 Maintenance — Stable95201
CF, Cycle 6 Maintenance — Improved3875
SF, Cycle 6 Maintenance — Worsened43106
SF, Cycle 6 Maintenance — Stable91162
SF, Cycle 6 Maintenance — Improved67142
Fatigue, Cycle 6 Maintenance — Worsened49132
Fatigue, Cycle 6 Maintenance — Stable59110
Fatigue, Cycle 6 Maintenance — Improved93167
N/V, Cycle 6 Maintenance — Worsened3691
N/V, Cycle 6 Maintenance — Stable126247
N/V, Cycle 6 Maintenance — Improved3971
Pain, Cycle 6 Maintenance — Worsened4496
Pain, Cycle 6 Maintenance — Stable85161
Pain, Cycle 6 Maintenance — Improved72153
Dyspnoea, Cycle 6 Maintenance — Worsened43105
Dyspnoea, Cycle 6 Maintenance — Stable125240
Dyspnoea, Cycle 6 Maintenance — Improved3363
Insomnia, Cycle 6 Maintenance — Worsened4388
Insomnia, Cycle 6 Maintenance — Stable99211
Insomnia, Cycle 6 Maintenance — Improved59110
AL, Cycle 6 Maintenance — Worsened2968
AL, Cycle 6 Maintenance — Stable111232
AL, Cycle 6 Maintenance — Improved61108
Constipation, Cycle 6 Maintenance — Worsened62106
Constipation, Cycle 6 Maintenance — Stable89207
Constipation, Cycle 6 Maintenance — Improved4993
Diarrhoea, Cycle 6 Maintenance — Worsened845
Diarrhoea, Cycle 6 Maintenance — Stable152293
Diarrhoea, Cycle 6 Maintenance — Improved4171
FD, Cycle 6 Maintenance — Worsened2150
FD, Cycle 6 Maintenance — Stable145299
FD, Cycle 6 Maintenance — Improved3560
GHS/QoL, Cycle 9 Maintenance — Worsened2276
GHS/QoL, Cycle 9 Maintenance — Stable100167
GHS/QoL, Cycle 9 Maintenance — Improved68127
PF, Cycle 9 Maintenance — Worsened3080
PF, Cycle 9 Maintenance — Stable91192
PF, Cycle 9 Maintenance — Improved6996
RF, Cycle 9 Maintenance — Worsened4184
RF, Cycle 9 Maintenance — Stable71140
RF, Cycle 9 Maintenance — Improved78145
EF, Cycle 9 Maintenance — Worsened2970
EF, Cycle 9 Maintenance — Stable105220
EF, Cycle 9 Maintenance — Improved5680
CF, Cycle 9 Maintenance — Worsened57113
CF, Cycle 9 Maintenance — Stable102183
CF, Cycle 9 Maintenance — Improved3174
SF, Cycle 9 Maintenance — Worsened3782
SF, Cycle 9 Maintenance — Stable88168
SF, Cycle 9 Maintenance — Improved65120
Fatigue, Cycle 9 Maintenance — Worsened52101
Fatigue, Cycle 9 Maintenance — Stable47105
Fatigue, Cycle 9 Maintenance — Improved91164
N/V, Cycle 9 Maintenance — Worsened3565
N/V, Cycle 9 Maintenance — Stable114234
N/V, Cycle 9 Maintenance — Improved4171
Pain, Cycle 9 Maintenance — Worsened3699
Pain, Cycle 9 Maintenance — Stable77145
Pain, Cycle 9 Maintenance — Improved77126
Dyspnoea, Cycle 9 Maintenance — Worsened3773
Dyspnoea, Cycle 9 Maintenance — Stable119223
Dyspnoea, Cycle 9 Maintenance — Improved3474
Insomnia, Cycle 9 Maintenance — Worsened4673
Insomnia, Cycle 9 Maintenance — Stable81184
Insomnia, Cycle 9 Maintenance — Improved63112
AL, Cycle 9 Maintenance — Worsened1458
AL, Cycle 9 Maintenance — Stable121199
AL, Cycle 9 Maintenance — Improved55113
Constipation, Cycle 9 Maintenance — Worsened6289
Constipation, Cycle 9 Maintenance — Stable83189
Constipation, Cycle 9 Maintenance — Improved4491
Diarrhoea, Cycle 9 Maintenance — Worsened1536
Diarrhoea, Cycle 9 Maintenance — Stable138264
Diarrhoea, Cycle 9 Maintenance — Improved3669
FD, Cycle 9 Maintenance — Worsened1842
FD, Cycle 9 Maintenance — Stable145276
FD, Cycle 9 Maintenance — Improved2751
GHS/QoL, Cycle 12 Maintenance — Worsened2364
GHS/QoL, Cycle 12 Maintenance — Stable69141
GHS/QoL, Cycle 12 Maintenance — Improved70111
PF, Cycle 12 Maintenance — Worsened2260
PF, Cycle 12 Maintenance — Stable82167
PF, Cycle 12 Maintenance — Improved5787
RF, Cycle 12 Maintenance — Worsened2957
RF, Cycle 12 Maintenance — Stable68127
RF, Cycle 12 Maintenance — Improved64129
EF, Cycle 12 Maintenance — Worsened3169
EF, Cycle 12 Maintenance — Stable82181
EF, Cycle 12 Maintenance — Improved4965
CF, Cycle 12 Maintenance — Worsened50106
CF, Cycle 12 Maintenance — Stable86154
CF, Cycle 12 Maintenance — Improved2655
SF, Cycle 12 Maintenance — Worsened2774
SF, Cycle 12 Maintenance — Stable69123
SF, Cycle 12 Maintenance — Improved66117
Fatigue, Cycle 12 Maintenance — Worsened3987
Fatigue, Cycle 12 Maintenance — Stable4288
Fatigue, Cycle 12 Maintenance — Improved80140
N/V, Cycle 12 Maintenance — Worsened2162
N/V, Cycle 12 Maintenance — Stable105190
N/V, Cycle 12 Maintenance — Improved3562
Pain, Cycle 12 Maintenance — Worsened33100
Pain, Cycle 12 Maintenance — Stable7197
Pain, Cycle 12 Maintenance — Improved58119
Dyspnoea, Cycle 12 Maintenance — Worsened2757
Dyspnoea, Cycle 12 Maintenance — Stable107197
Dyspnoea, Cycle 12 Maintenance — Improved2660
Insomnia, Cycle 12 Maintenance — Worsened2869
Insomnia, Cycle 12 Maintenance — Stable80161
Insomnia, Cycle 12 Maintenance — Improved5384
AL, Cycle 12 Maintenance — Worsened1249
AL, Cycle 12 Maintenance — Stable99173
AL, Cycle 12 Maintenance — Improved5092
Constipation, Cycle 12 Maintenance — Worsened3890
Constipation, Cycle 12 Maintenance — Stable79150
Constipation, Cycle 12 Maintenance — Improved4474
Diarrhoea, Cycle 12 Maintenance — Worsened1242
Diarrhoea, Cycle 12 Maintenance — Stable119221
Diarrhoea, Cycle 12 Maintenance — Improved3153
FD, Cycle 12 Maintenance — Worsened1741
FD, Cycle 12 Maintenance — Stable126222
FD, Cycle 12 Maintenance — Improved1950
GHS/QoL, Cycle 15 Maintenance — Worsened2660
GHS/QoL, Cycle 15 Maintenance — Stable67142
GHS/QoL, Cycle 15 Maintenance — Improved6085
PF, Cycle 15 Maintenance — Worsened2463
PF, Cycle 15 Maintenance — Stable67137
PF, Cycle 15 Maintenance — Improved6085
RF, Cycle 15 Maintenance — Worsened2560
RF, Cycle 15 Maintenance — Stable60108
RF, Cycle 15 Maintenance — Improved68118
EF, Cycle 15 Maintenance — Worsened3759
EF, Cycle 15 Maintenance — Stable78160
EF, Cycle 15 Maintenance — Improved3768
CF, Cycle 15 Maintenance — Worsened54111
CF, Cycle 15 Maintenance — Stable78120
CF, Cycle 15 Maintenance — Improved2156
SF, Cycle 15 Maintenance — Worsened2761
SF, Cycle 15 Maintenance — Stable70121
SF, Cycle 15 Maintenance — Improved56105
Fatigue, Cycle 15 Maintenance — Worsened3881
Fatigue, Cycle 15 Maintenance — Stable4074
Fatigue, Cycle 15 Maintenance — Improved75132
N/V, Cycle 15 Maintenance — Worsened2947
N/V, Cycle 15 Maintenance — Stable92179
N/V, Cycle 15 Maintenance — Improved3259
Pain, Cycle 15 Maintenance — Worsened3871
Pain, Cycle 15 Maintenance — Stable58102
Pain, Cycle 15 Maintenance — Improved57114
Dyspnoea, Cycle 15 Maintenance — Worsened2859
Dyspnoea, Cycle 15 Maintenance — Stable95172
Dyspnoea, Cycle 15 Maintenance — Improved2956
Insomnia, Cycle 15 Maintenance — Worsened3765
Insomnia, Cycle 15 Maintenance — Stable73128
Insomnia, Cycle 15 Maintenance — Improved4393
AL, Cycle 15 Maintenance — Worsened1329
AL, Cycle 15 Maintenance — Stable89164
AL, Cycle 15 Maintenance — Improved5092
Constipation, Cycle 15 Maintenance — Worsened3866
Constipation, Cycle 15 Maintenance — Stable76147
Constipation, Cycle 15 Maintenance — Improved3973
Diarrhoea, Cycle 15 Maintenance — Worsened1229
Diarrhoea, Cycle 15 Maintenance — Stable116200
Diarrhoea, Cycle 15 Maintenance — Improved2558
FD, Cycle 15 Maintenance — Worsened1647
FD, Cycle 15 Maintenance — Stable116195
FD, Cycle 15 Maintenance — Improved2044
GHS/QoL, Cycle 17 Maintenance — Worsened413
GHS/QoL, Cycle 17 Maintenance — Stable2433
GHS/QoL, Cycle 17 Maintenance — Improved1239
PF, Cycle 17 Maintenance — Worsened713
PF, Cycle 17 Maintenance — Stable2038
PF, Cycle 17 Maintenance — Improved1334
RF, Cycle 17 Maintenance — Worsened1020
RF, Cycle 17 Maintenance — Stable1424
RF, Cycle 17 Maintenance — Improved1641
EF, Cycle 17 Maintenance — Worsened415
EF, Cycle 17 Maintenance — Stable2050
EF, Cycle 17 Maintenance — Improved1620
CF, Cycle 17 Maintenance — Worsened1332
CF, Cycle 17 Maintenance — Stable2142
CF, Cycle 17 Maintenance — Improved611
SF, Cycle 17 Maintenance — Worsened622
SF, Cycle 17 Maintenance — Stable2029
SF, Cycle 17 Maintenance — Improved1434
Fatigue, Cycle 17 Maintenance — Worsened620
Fatigue, Cycle 17 Maintenance — Stable1427
Fatigue, Cycle 17 Maintenance — Improved2038
N/V, Cycle 17 Maintenance — Worsened817
N/V, Cycle 17 Maintenance — Stable2242
N/V, Cycle 17 Maintenance — Improved1026
Pain, Cycle 17 Maintenance — Worsened823
Pain, Cycle 17 Maintenance — Stable1326
Pain, Cycle 17 Maintenance — Improved1936
Dyspnoea, Cycle 17 Maintenance — Worsened619
Dyspnoea, Cycle 17 Maintenance — Stable2549
Dyspnoea, Cycle 17 Maintenance — Improved917
Insomnia, Cycle 17 Maintenance — Worsened818
Insomnia, Cycle 17 Maintenance — Stable1938
Insomnia, Cycle 17 Maintenance — Improved1329
AL, Cycle 17 Maintenance — Worsened66
AL, Cycle 17 Maintenance — Stable2751
AL, Cycle 17 Maintenance — Improved728
Constipation, Cycle 17 Maintenance — Worsened619
Constipation, Cycle 17 Maintenance — Stable2239
Constipation, Cycle 17 Maintenance — Improved1227
Diarrhoea, Cycle 17 Maintenance — Worsened710
Diarrhoea, Cycle 17 Maintenance — Stable2460
Diarrhoea, Cycle 17 Maintenance — Improved915
FD, Cycle 17 Maintenance — Worsened711
FD, Cycle 17 Maintenance — Stable2659
FD, Cycle 17 Maintenance — Improved715
GHS/QoL, Cycle 23 Maintenance — Worsened916
GHS/QoL, Cycle 23 Maintenance — Stable2737
GHS/QoL, Cycle 23 Maintenance — Improved1949
PF, Cycle 23 Maintenance — Worsened1017
PF, Cycle 23 Maintenance — Stable2945
PF, Cycle 23 Maintenance — Improved1638
RF, Cycle 23 Maintenance — Worsened1221
RF, Cycle 23 Maintenance — Stable2333
RF, Cycle 23 Maintenance — Improved2045
EF, Cycle 23 Maintenance — Worsened1019
EF, Cycle 23 Maintenance — Stable3357
EF, Cycle 23 Maintenance — Improved1225
CF, Cycle 23 Maintenance — Worsened1537
CF, Cycle 23 Maintenance — Stable2848
CF, Cycle 23 Maintenance — Improved1217
SF, Cycle 23 Maintenance — Worsened1224
SF, Cycle 23 Maintenance — Stable3135
SF, Cycle 23 Maintenance — Improved1243
Fatigue, Cycle 23 Maintenance — Worsened1025
Fatigue, Cycle 23 Maintenance — Stable1527
Fatigue, Cycle 23 Maintenance — Improved3049
N/V, Cycle 23 Maintenance — Worsened815
N/V, Cycle 23 Maintenance — Stable3663
N/V, Cycle 23 Maintenance — Improved1123
Pain, Cycle 23 Maintenance — Worsened1322
Pain, Cycle 23 Maintenance — Stable1939
Pain, Cycle 23 Maintenance — Improved2340
Dyspnoea, Cycle 23 Maintenance — Worsened715
Dyspnoea, Cycle 23 Maintenance — Stable3762
Dyspnoea, Cycle 23 Maintenance — Improved1123
Insomnia, Cycle 23 Maintenance — Worsened1020
Insomnia, Cycle 23 Maintenance — Stable2743
Insomnia, Cycle 23 Maintenance — Improved1839
AL, Cycle 23 Maintenance — Worsened612
AL, Cycle 23 Maintenance — Stable4058
AL, Cycle 23 Maintenance — Improved930
Constipation, Cycle 23 Maintenance — Worsened827
Constipation, Cycle 23 Maintenance — Stable3449
Constipation, Cycle 23 Maintenance — Improved1323
Diarrhoea, Cycle 23 Maintenance — Worsened49
Diarrhoea, Cycle 23 Maintenance — Stable4170
Diarrhoea, Cycle 23 Maintenance — Improved1022
FD, Cycle 23 Maintenance — Worsened718
FD, Cycle 23 Maintenance — Stable4265
FD, Cycle 23 Maintenance — Improved618
GHS/QoL, Cycle 29 Maintenance — Worsened521
GHS/QoL, Cycle 29 Maintenance — Stable2737
GHS/QoL, Cycle 29 Maintenance — Improved2040
PF, Cycle 29 Maintenance 20 — Worsened417
PF, Cycle 29 Maintenance 20 — Stable2950
PF, Cycle 29 Maintenance 20 — Improved1930
RF, Cycle 29 Maintenance — Worsened520
RF, Cycle 29 Maintenance — Stable2240
RF, Cycle 29 Maintenance — Improved2537
EF, Cycle 29 Maintenance — Worsened521
EF, Cycle 29 Maintenance — Stable3258
EF, Cycle 29 Maintenance — Improved1519
CF, Cycle 29 Maintenance — Worsened1135
CF, Cycle 29 Maintenance — Stable2946
CF, Cycle 29 Maintenance — Improved1217
SF, Cycle 29 Maintenance — Worsened1224
SF, Cycle 29 Maintenance — Stable2037
SF, Cycle 29 Maintenance — Improved2037
Fatigue, Cycle 29 Maintenance — Worsened1024
Fatigue, Cycle 29 Maintenance — Stable1722
Fatigue, Cycle 29 Maintenance — Improved2551
N/V, Cycle 29 Maintenance — Worsened49
N/V, Cycle 29 Maintenance — Stable3764
N/V, Cycle 29 Maintenance — Improved1124
Pain, Cycle 29 Maintenance — Worsened1027
Pain, Cycle 29 Maintenance — Stable2043
Pain, Cycle 29 Maintenance — Improved2128
Dyspnoea, Cycle 29 Maintenance — Worsened917
Dyspnoea, Cycle 29 Maintenance — Stable3066
Dyspnoea, Cycle 29 Maintenance — Improved1213
Insomnia, Cycle 29 Maintenance — Worsened1424
Insomnia, Cycle 29 Maintenance — Stable2447
Insomnia, Cycle 29 Maintenance — Improved1426
AL, Cycle 29 Maintenance — Worsened48
AL, Cycle 29 Maintenance — Stable3758
AL, Cycle 29 Maintenance — Improved1130
Constipation, Cycle 29 Maintenance — Worsened519
Constipation, Cycle 29 Maintenance — Stable2960
Constipation, Cycle 29 Maintenance — Improved1818
Diarrhoea, Cycle 29 Maintenance — Worsened36
Diarrhoea, Cycle 29 Maintenance — Stable3976
Diarrhoea, Cycle 29 Maintenance — Improved1016
FD, Cycle 29 Maintenance — Worsened213
FD, Cycle 29 Maintenance — Stable4266
FD, Cycle 29 Maintenance — Improved819
GHS/QoL, Cycle 35 Maintenance — Worsened417
GHS/QoL, Cycle 35 Maintenance — Stable2438
GHS/QoL, Cycle 35 Maintenance — Improved1634
PF, Cycle 35 Maintenance — Worsened919
PF, Cycle 35 Maintenance — Stable1945
PF, Cycle 35 Maintenance — Improved1626
RF, Cycle 35 Maintenance — Worsened622
RF, Cycle 35 Maintenance — Stable2135
RF, Cycle 35 Maintenance — Improved1732
EF, Cycle 35 Maintenance — Worsened816
EF, Cycle 35 Maintenance — Stable2451
EF, Cycle 35 Maintenance — Improved1222
CF, Cycle 35 Maintenance — Worsened1529
CF, Cycle 35 Maintenance — Stable2343
CF, Cycle 35 Maintenance — Improved617
SF, Cycle 35 Maintenance — Worsened1118
SF, Cycle 35 Maintenance — Stable2129
SF, Cycle 35 Maintenance — Improved1242
Fatigue, Cycle 35 Maintenance — Worsened1025
Fatigue, Cycle 35 Maintenance — Stable1023
Fatigue, Cycle 35 Maintenance — Improved2441
N/V, Cycle 35 Maintenance — Worsened617
N/V, Cycle 35 Maintenance — Stable3353
N/V, Cycle 35 Maintenance — Improved518
Pain, Cycle 35 Maintenance — Worsened630
Pain, Cycle 35 Maintenance — Stable1933
Pain, Cycle 35 Maintenance — Improved1927
Dyspnoea, Cycle 35 Maintenance — Worsened821
Dyspnoea, Cycle 35 Maintenance — Stable3057
Dyspnoea, Cycle 35 Maintenance — Improved611
Insomnia, Cycle 35 Maintenance — Worsened1522
Insomnia, Cycle 35 Maintenance — Stable2041
Insomnia, Cycle 35 Maintenance — Improved926
AL, Cycle 35 Maintenance — Worsened37
AL, Cycle 35 Maintenance — Stable3651
AL, Cycle 35 Maintenance — Improved529
Constipation, Cycle 35 Maintenance — Worsened519
Constipation, Cycle 35 Maintenance — Stable2748
Constipation, Cycle 35 Maintenance — Improved1220
Diarrhoea, Cycle 35 Maintenance — Worsened48
Diarrhoea, Cycle 35 Maintenance — Stable3569
Diarrhoea, Cycle 35 Maintenance — Improved511
FD, Cycle 35 Maintenance — Worsened615
FD, Cycle 35 Maintenance — Stable3053
FD, Cycle 35 Maintenance — Improved821
GHS/QoL, Cycle 41 Maintenance — Worsened1022
GHS/QoL, Cycle 41 Maintenance — Stable2646
GHS/QoL, Cycle 41 Maintenance — Improved2239
PF, Cycle 41 Maintenance — Worsened526
PF, Cycle 41 Maintenance — Stable3254
PF, Cycle 41 Maintenance — Improved2126
RF, Cycle 41 Maintenance — Worsened929
RF, Cycle 41 Maintenance — Stable2538
RF, Cycle 41 Maintenance — Improved2439
EF, Cycle 41 Maintenance — Worsened1023
EF, Cycle 41 Maintenance — Stable3555
EF, Cycle 41 Maintenance — Improved1329
CF, Cycle 41 Maintenance — Worsened2342
CF, Cycle 41 Maintenance — Stable2546
CF, Cycle 41 Maintenance — Improved1019
SF, Cycle 41 Maintenance — Worsened1328
SF, Cycle 41 Maintenance — Stable2538
SF, Cycle 41 Maintenance — Improved2041
Fatigue, Cycle 41 Maintenance — Worsened1135
Fatigue, Cycle 41 Maintenance — Stable1727
Fatigue, Cycle 41 Maintenance — Improved3044
N/V, Cycle 41 Maintenance — Worsened817
N/V, Cycle 41 Maintenance — Stable3966
N/V, Cycle 41 Maintenance — Improved1124
Pain, Cycle 41 Maintenance — Worsened1135
Pain, Cycle 41 Maintenance — Stable2341
Pain, Cycle 41 Maintenance — Improved2431
Dyspnoea, Cycle 41 Maintenance — Worsened826
Dyspnoea, Cycle 41 Maintenance — Stable3971
Dyspnoea, Cycle 41 Maintenance — Improved1110
Insomnia, Cycle 41 Maintenance — Worsened1630
Insomnia, Cycle 41 Maintenance — Stable2552
Insomnia, Cycle 41 Maintenance — Improved1725
AL, Cycle 41 Maintenance — Worsened914
AL, Cycle 41 Maintenance — Stable3860
AL, Cycle 41 Maintenance — Improved1133
Constipation, Cycle 41 Maintenance — Worsened1228
Constipation, Cycle 41 Maintenance — Stable3347
Constipation, Cycle 41 Maintenance — Improved1332
Diarrhoea, Cycle 41 Maintenance — Worsened55
Diarrhoea, Cycle 41 Maintenance — Stable4485
Diarrhoea, Cycle 41 Maintenance — Improved917
FD, Cycle 41 Maintenance — Worsened818
FD, Cycle 41 Maintenance — Stable4269
FD, Cycle 41 Maintenance — Improved820
GHS/QoL, Cycle 47 Maintenance — Worsened516
GHS/QoL, Cycle 47 Maintenance — Stable2641
GHS/QoL, Cycle 47 Maintenance — Improved1732
PF, Cycle 47 Maintenance — Worsened417
PF, Cycle 47 Maintenance — Stable3049
PF, Cycle 47 Maintenance — Improved1421
RF, Cycle 47 Maintenance — Worsened817
RF, Cycle 47 Maintenance — Stable2338
RF, Cycle 47 Maintenance — Improved1732
EF, Cycle 47 Maintenance — Worsened417
EF, Cycle 47 Maintenance — Stable2948
EF, Cycle 47 Maintenance — Improved1524
CF, Cycle 47 Maintenance — Worsened1828
CF, Cycle 47 Maintenance — Stable2448
CF, Cycle 47 Maintenance — Improved613
SF, Cycle 47 Maintenance — Worsened517
SF, Cycle 47 Maintenance — Stable2738
SF, Cycle 47 Maintenance — Improved1634
Fatigue, Cycle 47 Maintenance — Worsened727
Fatigue, Cycle 47 Maintenance — Stable1121
Fatigue, Cycle 47 Maintenance — Improved3040
N/V, Cycle 47 Maintenance — Worsened914
N/V, Cycle 47 Maintenance — Stable3257
N/V, Cycle 47 Maintenance — Improved718
Pain, Cycle 47 Maintenance — Worsened1125
Pain, Cycle 47 Maintenance — Stable1839
Pain, Cycle 47 Maintenance — Improved1925
Dyspnoea, Cycle 47 Maintenance — Worsened620
Dyspnoea, Cycle 47 Maintenance — Stable3458
Dyspnoea, Cycle 47 Maintenance — Improved811
Insomnia, Cycle 47 Maintenance — Worsened1125
Insomnia, Cycle 47 Maintenance — Stable2339
Insomnia, Cycle 47 Maintenance — Improved1425
AL, Cycle 47 Maintenance — Worsened212
AL, Cycle 47 Maintenance — Stable3748
AL, Cycle 47 Maintenance — Improved929
Constipation, Cycle 47 Maintenance — Worsened1321
Constipation, Cycle 47 Maintenance — Stable2544
Constipation, Cycle 47 Maintenance — Improved1024
Diarrhoea, Cycle 47 Maintenance — Worsened68
Diarrhoea, Cycle 47 Maintenance — Stable3566
Diarrhoea, Cycle 47 Maintenance — Improved715
FD, Cycle 47 Maintenance — Worsened616
FD, Cycle 47 Maintenance — Stable3757
FD, Cycle 47 Maintenance — Improved516
GHS/QoL, Cycle 53 Maintenance — Worsened312
GHS/QoL, Cycle 53 Maintenance — Stable1118
GHS/QoL, Cycle 53 Maintenance — Improved1224
PF, Cycle 53 Maintenance — Worsened411
PF, Cycle 53 Maintenance — Stable1131
PF, Cycle 53 Maintenance — Improved1112
RF, Cycle 53 Maintenance — Worsened516
RF, Cycle 53 Maintenance — Stable1122
RF, Cycle 53 Maintenance — Improved1016
EF, Cycle 53 Maintenance — Worsened315
EF, Cycle 53 Maintenance — Stable1723
EF, Cycle 53 Maintenance — Improved616
CF, Cycle 53 Maintenance — Worsened1019
CF, Cycle 53 Maintenance — Stable1325
CF, Cycle 53 Maintenance — Improved310
SF, Cycle 53 Maintenance — Worsened711
SF, Cycle 53 Maintenance — Stable1223
SF, Cycle 53 Maintenance — Improved720
Fatigue, Cycle 53 Maintenance — Worsened314
Fatigue, Cycle 53 Maintenance — Stable718
Fatigue, Cycle 53 Maintenance — Improved1622
N/V, Cycle 53 Maintenance — Worsened37
N/V, Cycle 53 Maintenance — Stable1936
N/V, Cycle 53 Maintenance — Improved411
Pain, Cycle 53 Maintenance — Worsened414
Pain, Cycle 53 Maintenance — Stable1227
Pain, Cycle 53 Maintenance — Improved1013
Dyspnoea, Cycle 53 Maintenance — Worsened312
Dyspnoea, Cycle 53 Maintenance — Stable1835
Dyspnoea, Cycle 53 Maintenance — Improved57
Insomnia, Cycle 53 Maintenance — Worsened812
Insomnia, Cycle 53 Maintenance — Stable1329
Insomnia, Cycle 53 Maintenance — Improved513
AL, Cycle 53 Maintenance — Worsened27
AL, Cycle 53 Maintenance — Stable2232
AL, Cycle 53 Maintenance — Improved215
Constipation, Cycle 53 Maintenance — Worsened79
Constipation, Cycle 53 Maintenance — Stable1430
Constipation, Cycle 53 Maintenance — Improved515
Diarrhoea, Cycle 53 Maintenance — Worsened25
Diarrhoea, Cycle 53 Maintenance — Stable2043
Diarrhoea, Cycle 53 Maintenance — Improved46
FD, Cycle 53 Maintenance — Worsened610
FD, Cycle 53 Maintenance — Stable1636
FD, Cycle 53 Maintenance — Improved48
GHS/QoL, Cycle 59 Maintenance — Worsened13
GHS/QoL, Cycle 59 Maintenance — Stable1112
GHS/QoL, Cycle 59 Maintenance — Improved621
PF, Cycle 59 Maintenance — Worsened39
PF, Cycle 59 Maintenance — Stable818
PF, Cycle 59 Maintenance — Improved79
RF, Cycle 59 Maintenance — Worsened38
RF, Cycle 59 Maintenance — Stable818
RF, Cycle 59 Maintenance — Improved710
EF, Cycle 59 Maintenance — Worsened46
EF, Cycle 59 Maintenance — Stable1118
EF, Cycle 59 Maintenance — Improved312
CF, Cycle 59 Maintenance — Worsened513
CF, Cycle 59 Maintenance — Stable1114
CF, Cycle 59 Maintenance — Improved29
SF, Cycle 59 Maintenance — Worsened46
SF, Cycle 59 Maintenance — Stable1012
SF, Cycle 59 Maintenance — Improved418
Fatigue, Cycle 59 Maintenance — Worsened47
Fatigue, Cycle 59 Maintenance — Stable810
Fatigue, Cycle 59 Maintenance — Improved619
N/V, Cycle 59 Maintenance — Worsened46
N/V, Cycle 59 Maintenance — Stable1221
N/V, Cycle 59 Maintenance — Improved29
Pain, Cycle 59 Maintenance — Worsened16
Pain, Cycle 59 Maintenance — Stable1021
Pain, Cycle 59 Maintenance — Improved79
Dyspnoea, Cycle 59 Maintenance — Worsened29
Dyspnoea, Cycle 59 Maintenance — Stable1224
Dyspnoea, Cycle 59 Maintenance — Improved43
Insomnia, Cycle 59 Maintenance — Worsened66
Insomnia, Cycle 59 Maintenance — Stable1015
Insomnia, Cycle 59 Maintenance — Improved215
AL, Cycle 59 Maintenance — Worsened13
AL, Cycle 59 Maintenance — Stable1621
AL, Cycle 59 Maintenance — Improved112
Constipation, Cycle 59 Maintenance — Worsened58
Constipation, Cycle 59 Maintenance — Stable1220
Constipation, Cycle 59 Maintenance — Improved18
Diarrhoea, Cycle 59 Maintenance — Worsened12
Diarrhoea, Cycle 59 Maintenance — Stable1429
Diarrhoea, Cycle 59 Maintenance — Improved35
FD, Cycle 59 Maintenance — Worsened34
FD, Cycle 59 Maintenance — Stable1122
FD, Cycle 59 Maintenance — Improved410
GHS/QoL, Cycle 65 Maintenance — Worsened13
GHS/QoL, Cycle 65 Maintenance — Stable77
GHS/QoL, Cycle 65 Maintenance — Improved417
PF, Cycle 65 Maintenance — Worsened110
PF, Cycle 65 Maintenance — Stable612
PF, Cycle 65 Maintenance — Improved55
RF, Cycle 65 Maintenance — Worsened27
RF, Cycle 65 Maintenance — Stable411
RF, Cycle 65 Maintenance — Improved69
EF, Cycle 65 Maintenance — Worsened03
EF, Cycle 65 Maintenance — Stable816
EF, Cycle 65 Maintenance — Improved48
CF, Cycle 65 Maintenance — Worsened38
CF, Cycle 65 Maintenance — Stable713
CF, Cycle 65 Maintenance — Improved26
SF, Cycle 65 Maintenance — Worsened46
SF, Cycle 65 Maintenance — Stable48
SF, Cycle 65 Maintenance — Improved413
Fatigue, Cycle 65 Maintenance — Worsened17
Fatigue, Cycle 65 Maintenance — Stable58
Fatigue, Cycle 65 Maintenance — Improved612
N/V, Cycle 65 Maintenance — Worsened12
N/V, Cycle 65 Maintenance — Stable919
N/V, Cycle 65 Maintenance — Improved26
Pain, Cycle 65 Maintenance — Worsened28
Pain, Cycle 65 Maintenance — Stable711
Pain, Cycle 65 Maintenance — Improved38
Dyspnoea, Cycle 65 Maintenance — Worsened210
Dyspnoea, Cycle 65 Maintenance — Stable915
Dyspnoea, Cycle 65 Maintenance — Improved12
Insomnia, Cycle 65 Maintenance — Worsened37
Insomnia, Cycle 65 Maintenance — Stable715
Insomnia, Cycle 65 Maintenance — Improved25
AL, Cycle 65 Maintenance — Worsened01
AL, Cycle 65 Maintenance — Stable1117
AL, Cycle 65 Maintenance — Improved19
Constipation, Cycle 65 Maintenance — Worsened66
Constipation, Cycle 65 Maintenance — Stable517
Constipation, Cycle 65 Maintenance — Improved14
Diarrhoea, Cycle 65 Maintenance — Worsened11
Diarrhoea, Cycle 65 Maintenance — Stable1022
Diarrhoea, Cycle 65 Maintenance — Improved14
FD, Cycle 65 Maintenance — Worsened15
FD, Cycle 65 Maintenance — Stable815
FD, Cycle 65 Maintenance — Improved36
GHS/QoL, Cycle 71 Maintenance — Worsened01
GHS/QoL, Cycle 71 Maintenance — Stable35
GHS/QoL, Cycle 71 Maintenance — Improved58
PF, Cycle 71 Maintenance — Worsened14
PF, Cycle 71 Maintenance — Stable49
PF, Cycle 71 Maintenance — Improved31
RF, Cycle 71 Maintenance — Worsened04
RF, Cycle 71 Maintenance — Stable46
RF, Cycle 71 Maintenance — Improved44
EF, Cycle 71 Maintenance — Worsened13
EF, Cycle 71 Maintenance — Stable69
EF, Cycle 71 Maintenance — Improved12
CF, Cycle 71 Maintenance — Worsened33
CF, Cycle 71 Maintenance — Stable59
CF, Cycle 71 Maintenance — Improved02
SF, Cycle 71 Maintenance — Worsened24
SF, Cycle 71 Maintenance — Stable24
SF, Cycle 71 Maintenance — Improved46
Fatigue, Cycle 71 Maintenance — Worsened03
Fatigue, Cycle 71 Maintenance — Stable34
Fatigue, Cycle 71 Maintenance — Improved57
N/V, Cycle 71 Maintenance — Worsened11
N/V, Cycle 71 Maintenance — Stable510
N/V, Cycle 71 Maintenance — Improved23
Pain, Cycle 71 Maintenance — Worsened02
Pain, Cycle 71 Maintenance — Stable49
Pain, Cycle 71 Maintenance — Improved43
Dyspnoea, Cycle 71 Maintenance — Worsened01
Dyspnoea, Cycle 71 Maintenance — Stable712
Dyspnoea, Cycle 71 Maintenance — Improved11
Insomnia, Cycle 71 Maintenance — Worsened23
Insomnia, Cycle 71 Maintenance — Stable48
Insomnia, Cycle 71 Maintenance — Improved23
AL, Cycle 71 Maintenance — Worsened02
AL, Cycle 71 Maintenance — Stable66
AL, Cycle 71 Maintenance — Improved26
Constipation, Cycle 71 Maintenance — Worsened24
Constipation, Cycle 71 Maintenance — Stable49
Constipation, Cycle 71 Maintenance — Improved21
Diarrhoea, Cycle 71 Maintenance — Worsened00
Diarrhoea, Cycle 71 Maintenance — Stable711
Diarrhoea, Cycle 71 Maintenance — Improved13
FD, Cycle 71 Maintenance — Worsened12
FD, Cycle 71 Maintenance — Stable412
FD, Cycle 71 Maintenance — Improved30
GHS/QoL, Cycle 77 Maintenance — Worsened00
GHS/QoL, Cycle 77 Maintenance — Stable23
GHS/QoL, Cycle 77 Maintenance — Improved28
PF, Cycle 77 Maintenance — Worsened02
PF, Cycle 77 Maintenance — Stable25
PF, Cycle 77 Maintenance — Improved24
RF, Cycle 77 Maintenance — Worsened02
RF, Cycle 77 Maintenance — Stable14
RF, Cycle 77 Maintenance — Improved35
EF, Cycle 77 Maintenance — Worsened11
EF, Cycle 77 Maintenance — Stable28
EF, Cycle 77 Maintenance — Improved12
CF, Cycle 77 Maintenance — Worsened22
CF, Cycle 77 Maintenance — Stable13
CF, Cycle 77 Maintenance — Improved16
SF, Cycle 77 Maintenance — Worsened12
SF, Cycle 77 Maintenance — Stable12
SF, Cycle 77 Maintenance — Improved27
Fatigue, Cycle 77 Maintenance — Worsened05
Fatigue, Cycle 77 Maintenance — Stable12
Fatigue, Cycle 77 Maintenance — Improved34
N/V, Cycle 77 Maintenance — Worsened02
N/V, Cycle 77 Maintenance — Stable37
N/V, Cycle 77 Maintenance — Improved12
Pain, Cycle 77 Maintenance — Worsened01
Pain, Cycle 77 Maintenance — Stable35
Pain, Cycle 77 Maintenance — Improved15
Dyspnoea, Cycle 77 Maintenance — Worsened03
Dyspnoea, Cycle 77 Maintenance — Stable37
Dyspnoea, Cycle 77 Maintenance — Improved11
Insomnia, Cycle 77 Maintenance — Worsened05
Insomnia, Cycle 77 Maintenance — Stable34
Insomnia, Cycle 77 Maintenance — Improved12
AL, Cycle 77 Maintenance — Worsened13
AL, Cycle 77 Maintenance — Stable24
AL, Cycle 77 Maintenance — Improved14
Constipation, Cycle 77 Maintenance — Worsened11
Constipation, Cycle 77 Maintenance — Stable38
Constipation, Cycle 77 Maintenance — Improved02
Diarrhoea, Cycle 77 Maintenance — Worsened00
Diarrhoea, Cycle 77 Maintenance — Stable38
Diarrhoea, Cycle 77 Maintenance — Improved13
FD, Cycle 77 Maintenance — Worsened11
FD, Cycle 77 Maintenance — Stable210
FD, Cycle 77 Maintenance — Improved10
GHS/QoL, Cycle 83 Maintenance — Worsened00
GHS/QoL, Cycle 83 Maintenance — Stable11
GHS/QoL, Cycle 83 Maintenance — Improved25
PF, Cycle 83 Maintenance — Worsened12
PF, Cycle 83 Maintenance — Stable11
PF, Cycle 83 Maintenance — Improved13
RF, Cycle 83 Maintenance — Worsened01
RF, Cycle 83 Maintenance — Stable22
RF, Cycle 83 Maintenance — Improved13
EF, Cycle 83 Maintenance — Worsened02
EF, Cycle 83 Maintenance — Stable33
EF, Cycle 83 Maintenance — Improved01
CF, Cycle 83 Maintenance — Worsened11
CF, Cycle 83 Maintenance — Stable23
CF, Cycle 83 Maintenance — Improved02
SF, Cycle 83 Maintenance — Worsened11
SF, Cycle 83 Maintenance — Stable11
SF, Cycle 83 Maintenance — Improved14
Fatigue, Cycle 83 Maintenance — Worsened01
Fatigue, Cycle 83 Maintenance — Stable01
Fatigue, Cycle 83 Maintenance — Improved34
N/V, Cycle 83 Maintenance — Worsened10
N/V, Cycle 83 Maintenance — Stable24
N/V, Cycle 83 Maintenance — Improved02
Pain, Cycle 83 Maintenance — Worsened01
Pain, Cycle 83 Maintenance — Stable22
Pain, Cycle 83 Maintenance — Improved13
Dyspnoea, Cycle 83 Maintenance — Worsened03
Dyspnoea, Cycle 83 Maintenance — Stable23
Dyspnoea, Cycle 83 Maintenance — Improved10
Insomnia, Cycle 83 Maintenance — Worsened02
Insomnia, Cycle 83 Maintenance — Stable33
Insomnia, Cycle 83 Maintenance — Improved01
AL, Cycle 83 Maintenance — Worsened01
AL, Cycle 83 Maintenance — Stable32
AL, Cycle 83 Maintenance — Improved03
Constipation, Cycle 83 Maintenance — Worsened20
Constipation, Cycle 83 Maintenance — Stable06
Constipation, Cycle 83 Maintenance — Improved10
Diarrhoea, Cycle 83 Maintenance — Worsened00
Diarrhoea, Cycle 83 Maintenance — Stable35
Diarrhoea, Cycle 83 Maintenance — Improved01
FD, Cycle 83 Maintenance — Worsened10
FD, Cycle 83 Maintenance — Stable15
FD, Cycle 83 Maintenance — Improved11
GHS/QoL, Cycle 89 Maintenance — Worsened00
GHS/QoL, Cycle 89 Maintenance — Stable00
GHS/QoL, Cycle 89 Maintenance — Improved02
PF, Cycle 89 Maintenance — Worsened00
PF, Cycle 89 Maintenance — Stable00
PF, Cycle 89 Maintenance — Improved02
RF, Cycle 89 Maintenance — Worsened00
RF, Cycle 89 Maintenance — Stable02
RF, Cycle 89 Maintenance — Improved00
EF, Cycle 89 Maintenance — Worsened00
EF, Cycle 89 Maintenance — Stable02
EF, Cycle 89 Maintenance — Improved00
CF, Cycle 89 Maintenance — Worsened00
CF, Cycle 89 Maintenance — Stable01
CF, Cycle 89 Maintenance — Improved01
SF, Cycle 89 Maintenance — Worsened00
SF, Cycle 89 Maintenance — Stable01
SF, Cycle 89 Maintenance — Improved01
Fatigue, Cycle 89 Maintenance — Worsened00
Fatigue, Cycle 89 Maintenance — Stable00
Fatigue, Cycle 89 Maintenance — Improved02
N/V, Cycle 89 Maintenance — Worsened00
N/V, Cycle 89 Maintenance — Stable01
N/V, Cycle 89 Maintenance — Improved01
Pain, Cycle 89 Maintenance — Worsened00
Pain, Cycle 89 Maintenance — Stable01
Pain, Cycle 89 Maintenance — Improved01
Dyspnoea, Cycle 89 Maintenance — Worsened00
Dyspnoea, Cycle 89 Maintenance — Stable02
Dyspnoea, Cycle 89 Maintenance — Improved00
Insomnia, Cycle 89 Maintenance — Worsened00
Insomnia, Cycle 89 Maintenance — Stable02
Insomnia, Cycle 89 Maintenance — Improved00
AL, Cycle 89 Maintenance — Worsened00
AL, Cycle 89 Maintenance — Stable00
AL, Cycle 89 Maintenance — Improved02
Constipation, Cycle 89 Maintenance — Worsened00
Constipation, Cycle 89 Maintenance — Stable02
Constipation, Cycle 89 Maintenance — Improved00
Diarrhoea, Cycle 89 Maintenance — Worsened00
Diarrhoea, Cycle 89 Maintenance — Stable02
Diarrhoea, Cycle 89 Maintenance — Improved00
FD, Cycle 89 Maintenance — Worsened00
FD, Cycle 89 Maintenance — Stable01
FD, Cycle 89 Maintenance — Improved01
GHS/QoL, End of treatment (EOT) — Worsened50111
GHS/QoL, End of treatment (EOT) — Stable81150
GHS/QoL, End of treatment (EOT) — Improved5384
PF, EOT — Worsened4484
PF, EOT — Stable80161
PF, EOT — Improved5997
RF, EOT — Worsened57102
RF, EOT — Stable64115
RF, EOT — Improved62125
EF, EOT — Worsened67133
EF, EOT — Stable92161
EF, EOT — Improved2551
CF, EOT — Worsened68127
CF, EOT — Stable92155
CF, EOT — Improved2463
SF, EOT — Worsened58119
SF, EOT — Stable68118
SF, EOT — Improved58108
Fatigue, EOT — Worsened66124
Fatigue, EOT — Stable4580
Fatigue, EOT — Improved73140
N/V, EOT — Worsened3872
N/V, EOT — Stable117204
N/V, EOT — Improved2968
Pain, EOT — Worsened6695
Pain, EOT — Stable50140
Pain, EOT — Improved68110
Dyspnoea, EOT — Worsened4797
Dyspnoea, EOT — Stable109185
Dyspnoea, EOT — Improved2860
Insomnia, EOT — Worsened4791
Insomnia, EOT — Stable81160
Insomnia, EOT — Improved5693
AL, EOT — Worsened4074
AL, EOT — Stable94188
AL, EOT — Improved4981
Constipation, EOT — Worsened4473
Constipation, EOT — Stable89172
Constipation, EOT — Improved5098
Diarrhoea, EOT — Worsened2461
Diarrhoea, EOT — Stable127225
Diarrhoea, EOT — Improved3359
FD, EOT — Worsened2859
FD, EOT — Stable130239
FD, EOT — Improved2545
GHS/QoL, Safety Follow-up — Worsened3697
GHS/QoL, Safety Follow-up — Stable71130
GHS/QoL, Safety Follow-up — Improved3963
PF, Safety Follow-up — Worsened4080
PF, Safety Follow-up — Stable66129
PF, Safety Follow-up — Improved4078
RF, Safety Follow-up — Worsened4699
RF, Safety Follow-up — Stable5587
RF, Safety Follow-up — Improved45102
EF, Safety Follow-up — Worsened44107
EF, Safety Follow-up — Stable72147
EF, Safety Follow-up — Improved3036
CF, Safety Follow-up — Worsened56112
CF, Safety Follow-up — Stable69119
CF, Safety Follow-up — Improved2159
SF, Safety Follow-up — Worsened42105
SF, Safety Follow-up — Stable59105
SF, Safety Follow-up — Improved4580
Fatigue, Safety Follow-up — Worsened54109
Fatigue, Safety Follow-up — Stable3175
Fatigue, Safety Follow-up — Improved61106
N/V, Safety Follow-up — Worsened3465
N/V, Safety Follow-up — Stable92169
N/V, Safety Follow-up — Improved2056
Pain, Safety Follow-up — Worsened50108
Pain, Safety Follow-up — Stable47101
Pain, Safety Follow-up — Improved4981
Dyspnoea, Safety Follow-up — Worsened3684
Dyspnoea, Safety Follow-up — Stable91158
Dyspnoea, Safety Follow-up — Improved1948
Insomnia, Safety Follow-up — Worsened2279
Insomnia, Safety Follow-up — Stable75132
Insomnia, Safety Follow-up — Improved4979
AL, Safety Follow-up — Worsened2874
AL, Safety Follow-up — Stable81140
AL, Safety Follow-up — Improved3775
Constipation, Safety Follow-up — Worsened3256
Constipation, Safety Follow-up — Stable72153
Constipation, Safety Follow-up — Improved4181
Diarrhoea, Safety Follow-up — Worsened2158
Diarrhoea, Safety Follow-up — Stable97184
Diarrhoea, Safety Follow-up — Improved2748
FD, Safety Follow-up — Worsened1946
FD, Safety Follow-up — Stable114199
FD, Safety Follow-up — Improved1242
GHS/QoL, LTFU (EOT + 3 months) — Worsened3984
GHS/QoL, LTFU (EOT + 3 months) — Stable5397
GHS/QoL, LTFU (EOT + 3 months) — Improved4369
PF, LTFU (EOT + 3 months) — Worsened4280
PF, LTFU (EOT + 3 months) — Stable66100
PF, LTFU (EOT + 3 months) — Improved2770
RF, LTFU (EOT + 3 months) — Worsened5270
RF, LTFU (EOT + 3 months) — Stable4284
RF, LTFU (EOT + 3 months) — Improved4195
EF, LTFU (EOT + 3 months) — Worsened3076
EF, LTFU (EOT + 3 months) — Stable76129
EF, LTFU (EOT + 3 months) — Improved2945
CF, LTFU (EOT + 3 months) — Worsened5596
CF, LTFU (EOT + 3 months) — Stable64110
CF, LTFU (EOT + 3 months) — Improved1644
SF, LTFU (EOT + 3 months) — Worsened4880
SF, LTFU (EOT + 3 months) — Stable5191
SF, LTFU (EOT + 3 months) — Improved3679
Fatigue, LTFU (EOT + 3 months) — Worsened5298
Fatigue, LTFU (EOT + 3 months) — Stable2858
Fatigue, LTFU (EOT + 3 months) — Improved5594
N/V, LTFU (EOT + 3 months) — Worsened2045
N/V, LTFU (EOT + 3 months) — Stable88155
N/V, LTFU (EOT + 3 months) — Improved2750
Pain, LTFU (EOT + 3 months) — Worsened4189
Pain, LTFU (EOT + 3 months) — Stable4287
Pain, LTFU (EOT + 3 months) — Improved5274
Dyspnoea, LTFU (EOT + 3 months) — Worsened3371
Dyspnoea, LTFU (EOT + 3 months) — Stable84141
Dyspnoea, LTFU (EOT + 3 months) — Improved1838
Insomnia, LTFU (EOT + 3 months) — Worsened2858
Insomnia, LTFU (EOT + 3 months) — Stable66111
Insomnia, LTFU (EOT + 3 months) — Improved4081
AL, LTFU (EOT + 3 months) — Worsened2548
AL, LTFU (EOT + 3 months) — Stable75130
AL, LTFU (EOT + 3 months) — Improved3571
Constipation, LTFU (EOT + 3 months) — Worsened2553
Constipation, LTFU (EOT + 3 months) — Stable64128
Constipation, LTFU (EOT + 3 months) — Improved4569
Diarrhoea, LTFU (EOT + 3 months) — Worsened2052
Diarrhoea, LTFU (EOT + 3 months) — Stable89157
Diarrhoea, LTFU (EOT + 3 months) — Improved2641
FD, LTFU (EOT + 3 months) — Worsened2443
FD, LTFU (EOT + 3 months) — Stable90169
FD, LTFU (EOT + 3 months) — Improved2138
GHS/QoL, LTFU (EOT + 9 months) — Worsened2460
GHS/QoL, LTFU (EOT + 9 months) — Stable5377
GHS/QoL, LTFU (EOT + 9 months) — Improved2947
PF, LTFU (EOT + 9 months) — Worsened3256
PF, LTFU (EOT + 9 months) — Stable5983
PF, LTFU (EOT + 9 months) — Improved1445
RF, LTFU (EOT + 9 months) — Worsened3763
RF, LTFU (EOT + 9 months) — Stable3759
RF, LTFU (EOT + 9 months) — Improved3262
EF, LTFU (EOT + 9 months) — Worsened3153
EF, LTFU (EOT + 9 months) — Stable5797
EF, LTFU (EOT + 9 months) — Improved1834
CF, LTFU (EOT + 9 months) — Worsened4265
CF, LTFU (EOT + 9 months) — Stable5589
CF, LTFU (EOT + 9 months) — Improved930
SF, LTFU (EOT + 9 months) — Worsened4062
SF, LTFU (EOT + 9 months) — Stable3769
SF, LTFU (EOT + 9 months) — Improved2953
Fatigue, LTFU (EOT + 9 months) — Worsened4373
Fatigue, LTFU (EOT + 9 months) — Stable2246
Fatigue, LTFU (EOT + 9 months) — Improved4164
N/V, LTFU (EOT + 9 months) — Worsened2140
N/V, LTFU (EOT + 9 months) — Stable68112
N/V, LTFU (EOT + 9 months) — Improved1731
Pain, LTFU (EOT + 9 months) — Worsened3370
Pain, LTFU (EOT + 9 months) — Stable4659
Pain, LTFU (EOT + 9 months) — Improved2755
Dyspnoea, LTFU (EOT + 9 months) — Worsened3448
Dyspnoea, LTFU (EOT + 9 months) — Stable59103
Dyspnoea, LTFU (EOT + 9 months) — Improved1331
Insomnia, LTFU (EOT + 9 months) — Worsened2444
Insomnia, LTFU (EOT + 9 months) — Stable5582
Insomnia, LTFU (EOT + 9 months) — Improved2757
AL, LTFU (EOT + 9 months) — Worsened2145
AL, LTFU (EOT + 9 months) — Stable5993
AL, LTFU (EOT + 9 months) — Improved2544
Constipation, LTFU (EOT + 9 months) — Worsened2343
Constipation, LTFU (EOT + 9 months) — Stable5085
Constipation, LTFU (EOT + 9 months) — Improved3354
Diarrhoea, LTFU (EOT + 9 months) — Worsened2135
Diarrhoea, LTFU (EOT + 9 months) — Stable65122
Diarrhoea, LTFU (EOT + 9 months) — Improved2027
FD, LTFU (EOT + 9 months) — Worsened1826
FD, LTFU (EOT + 9 months) — Stable67129
FD, LTFU (EOT + 9 months) — Improved2128
GHS/QoL, LTFU (EOT + 15 months) — Worsened2348
GHS/QoL, LTFU (EOT + 15 months) — Stable3466
GHS/QoL, LTFU (EOT + 15 months) — Improved1939
PF, LTFU (EOT + 15 months) — Worsened2344
PF, LTFU (EOT + 15 months) — Stable3871
PF, LTFU (EOT + 15 months) — Improved1339
RF, LTFU (EOT + 15 months) — Worsened2946
RF, LTFU (EOT + 15 months) — Stable2266
RF, LTFU (EOT + 15 months) — Improved2542
EF, LTFU (EOT + 15 months) — Worsened2340
EF, LTFU (EOT + 15 months) — Stable4286
EF, LTFU (EOT + 15 months) — Improved1128
CF, LTFU (EOT + 15 months) — Worsened2355
CF, LTFU (EOT + 15 months) — Stable4370
CF, LTFU (EOT + 15 months) — Improved1029
SF, LTFU (EOT + 15 months) — Worsened3151
SF, LTFU (EOT + 15 months) — Stable2358
SF, LTFU (EOT + 15 months) — Improved2244
Fatigue, LTFU (EOT + 15 months) — Worsened2963
Fatigue, LTFU (EOT + 15 months) — Stable1439
Fatigue, LTFU (EOT + 15 months) — Improved3352
N/V, LTFU (EOT + 15 months) — Worsened1930
N/V, LTFU (EOT + 15 months) — Stable49101
N/V, LTFU (EOT + 15 months) — Improved823
Pain, LTFU (EOT + 15 months) — Worsened2161
Pain, LTFU (EOT + 15 months) — Stable3054
Pain, LTFU (EOT + 15 months) — Improved2539
Dyspnoea, LTFU (EOT + 15 months) — Worsened2447
Dyspnoea, LTFU (EOT + 15 months) — Stable4382
Dyspnoea, LTFU (EOT + 15 months) — Improved925
Insomnia, LTFU (EOT + 15 months) — Worsened1935
Insomnia, LTFU (EOT + 15 months) — Stable3271
Insomnia, LTFU (EOT + 15 months) — Improved2448
AL, LTFU (EOT + 15 months) — Worsened1327
AL, LTFU (EOT + 15 months) — Stable4087
AL, LTFU (EOT + 15 months) — Improved2339
Constipation, LTFU (EOT + 15 months) — Worsened2032
Constipation, LTFU (EOT + 15 months) — Stable3573
Constipation, LTFU (EOT + 15 months) — Improved2149
Diarrhoea, LTFU (EOT + 15 months) — Worsened1223
Diarrhoea, LTFU (EOT + 15 months) — Stable52103
Diarrhoea, LTFU (EOT + 15 months) — Improved1228
FD, LTFU (EOT + 15 months) — Worsened926
FD, LTFU (EOT + 15 months) — Stable54105
FD, LTFU (EOT + 15 months) — Improved1322
GHS/QoL, LTFU (EOT + 21 months) — Worsened1936
GHS/QoL, LTFU (EOT + 21 months) — Stable1437
GHS/QoL, LTFU (EOT + 21 months) — Improved1526
PF, LTFU (EOT + 21 months) — Worsened1533
PF, LTFU (EOT + 21 months) — Stable2541
PF, LTFU (EOT + 21 months) — Improved824
RF, LTFU (EOT + 21 months) — Worsened1535
RF, LTFU (EOT + 21 months) — Stable1630
RF, LTFU (EOT + 21 months) — Improved1734
EF, LTFU (EOT + 21 months) — Worsened1627
EF, LTFU (EOT + 21 months) — Stable2844
EF, LTFU (EOT + 21 months) — Improved428
CF, LTFU (EOT + 21 months) — Worsened1840
CF, LTFU (EOT + 21 months) — Stable2439
CF, LTFU (EOT + 21 months) — Improved620
SF, LTFU (EOT + 21 months) — Worsened1343
SF, LTFU (EOT + 21 months) — Stable2032
SF, LTFU (EOT + 21 months) — Improved1524
Fatigue, LTFU (EOT + 21 months) — Worsened2242
Fatigue, LTFU (EOT + 21 months) — Stable926
Fatigue, LTFU (EOT + 21 months) — Improved1731
N/V, LTFU (EOT + 21 months) — Worsened1323
N/V, LTFU (EOT + 21 months) — Stable2861
N/V, LTFU (EOT + 21 months) — Improved715
Pain, LTFU (EOT + 21 months) — Worsened1634
Pain, LTFU (EOT + 21 months) — Stable1434
Pain, LTFU (EOT + 21 months) — Improved1831
Dyspnoea, LTFU (EOT + 21 months) — Worsened1827
Dyspnoea, LTFU (EOT + 21 months) — Stable2458
Dyspnoea, LTFU (EOT + 21 months) — Improved614
Insomnia, LTFU (EOT + 21 months) — Worsened1425
Insomnia, LTFU (EOT + 21 months) — Stable2241
Insomnia, LTFU (EOT + 21 months) — Improved1233
AL, LTFU (EOT + 21 months) — Worsened1121
AL, LTFU (EOT + 21 months) — Stable2456
AL, LTFU (EOT + 21 months) — Improved1322
Constipation, LTFU (EOT + 21 months) — Worsened827
Constipation, LTFU (EOT + 21 months) — Stable2245
Constipation, LTFU (EOT + 21 months) — Improved1827
Diarrhoea, LTFU (EOT + 21 months) — Worsened1217
Diarrhoea, LTFU (EOT + 21 months) — Stable3262
Diarrhoea, LTFU (EOT + 21 months) — Improved420
FD, LTFU (EOT + 21 months) — Worsened518
FD, LTFU (EOT + 21 months) — Stable3368
FD, LTFU (EOT + 21 months) — Improved913
GHS/QoL, LTFU (EOT + 27 months) — Worsened917
GHS/QoL, LTFU (EOT + 27 months) — Stable1532
GHS/QoL, LTFU (EOT + 27 months) — Improved1221
PF, LTFU (EOT + 27 months) — Worsened1322
PF, LTFU (EOT + 27 months) — Stable1632
PF, LTFU (EOT + 27 months) — Improved716
RF, LTFU (EOT + 27 months) — Worsened920
RF, LTFU (EOT + 27 months) — Stable1322
RF, LTFU (EOT + 27 months) — Improved1428
EF, LTFU (EOT + 27 months) — Worsened920
EF, LTFU (EOT + 27 months) — Stable2131
EF, LTFU (EOT + 27 months) — Improved619
CF, LTFU (EOT + 27 months) — Worsened1227
CF, LTFU (EOT + 27 months) — Stable1628
CF, LTFU (EOT + 27 months) — Improved815
SF, LTFU (EOT + 27 months) — Worsened1428
SF, LTFU (EOT + 27 months) — Stable1121
SF, LTFU (EOT + 27 months) — Improved1121
Fatigue, LTFU (EOT + 27 months) — Worsened1425
Fatigue, LTFU (EOT + 27 months) — Stable718
Fatigue, LTFU (EOT + 27 months) — Improved1527
N/V, LTFU (EOT + 27 months) — Worsened712
N/V, LTFU (EOT + 27 months) — Stable2546
N/V, LTFU (EOT + 27 months) — Improved412
Pain, LTFU (EOT + 27 months) — Worsened928
Pain, LTFU (EOT + 27 months) — Stable1318
Pain, LTFU (EOT + 27 months) — Improved1424
Dyspnoea, LTFU (EOT + 27 months) — Worsened1117
Dyspnoea, LTFU (EOT + 27 months) — Stable1943
Dyspnoea, LTFU (EOT + 27 months) — Improved610
Insomnia, LTFU (EOT + 27 months) — Worsened816
Insomnia, LTFU (EOT + 27 months) — Stable1831
Insomnia, LTFU (EOT + 27 months) — Improved1023
AL, LTFU (EOT + 27 months) — Worsened913
AL, LTFU (EOT + 27 months) — Stable1644
AL, LTFU (EOT + 27 months) — Improved1113
Constipation, LTFU (EOT + 27 months) — Worsened515
Constipation, LTFU (EOT + 27 months) — Stable1733
Constipation, LTFU (EOT + 27 months) — Improved1422
Diarrhoea, LTFU (EOT + 27 months) — Worsened812
Diarrhoea, LTFU (EOT + 27 months) — Stable2543
Diarrhoea, LTFU (EOT + 27 months) — Improved315
FD, LTFU (EOT + 27 months) — Worsened411
FD, LTFU (EOT + 27 months) — Stable2549
FD, LTFU (EOT + 27 months) — Improved710
GHS/QoL, LTFU (EOT + 33 months) — Worsened48
GHS/QoL, LTFU (EOT + 33 months) — Stable620
GHS/QoL, LTFU (EOT + 33 months) — Improved610
PF, LTFU (EOT + 33 months) — Worsened510
PF, LTFU (EOT + 33 months) — Stable914
PF, LTFU (EOT + 33 months) — Improved215
RF, LTFU (EOT + 33 months) — Worsened412
RF, LTFU (EOT + 33 months) — Stable813
RF, LTFU (EOT + 33 months) — Improved414
EF, LTFU (EOT + 33 months) — Worsened54
EF, LTFU (EOT + 33 months) — Stable824
EF, LTFU (EOT + 33 months) — Improved310
CF, LTFU (EOT + 33 months) — Worsened515
CF, LTFU (EOT + 33 months) — Stable915
CF, LTFU (EOT + 33 months) — Improved28
SF, LTFU (EOT + 33 months) — Worsened514
SF, LTFU (EOT + 33 months) — Stable615
SF, LTFU (EOT + 33 months) — Improved59
Fatigue, LTFU (EOT + 33 months) — Worsened511
Fatigue, LTFU (EOT + 33 months) — Stable212
Fatigue, LTFU (EOT + 33 months) — Improved916
N/V, LTFU (EOT + 33 months) — Worsened47
N/V, LTFU (EOT + 33 months) — Stable1124
N/V, LTFU (EOT + 33 months) — Improved18
Pain, LTFU (EOT + 33 months) — Worsened216
Pain, LTFU (EOT + 33 months) — Stable710
Pain, LTFU (EOT + 33 months) — Improved713
Dyspnoea, LTFU (EOT + 33 months) — Worsened510
Dyspnoea, LTFU (EOT + 33 months) — Stable921
Dyspnoea, LTFU (EOT + 33 months) — Improved28
Insomnia, LTFU (EOT + 33 months) — Worsened36
Insomnia, LTFU (EOT + 33 months) — Stable915
Insomnia, LTFU (EOT + 33 months) — Improved417
AL, LTFU (EOT + 33 months) — Worsened63
AL, LTFU (EOT + 33 months) — Stable728
AL, LTFU (EOT + 33 months) — Improved38
Constipation, LTFU (EOT + 33 months) — Worsened210
Constipation, LTFU (EOT + 33 months) — Stable719
Constipation, LTFU (EOT + 33 months) — Improved710
Diarrhoea, LTFU (EOT + 33 months) — Worsened53
Diarrhoea, LTFU (EOT + 33 months) — Stable1026
Diarrhoea, LTFU (EOT + 33 months) — Improved19
FD, LTFU (EOT + 33 months) — Worsened26
FD, LTFU (EOT + 33 months) — Stable1026
FD, LTFU (EOT + 33 months) — Improved46
GHS/QoL, LTFU (EOT + 39 months) — Worsened37
GHS/QoL, LTFU (EOT + 39 months) — Stable314
GHS/QoL, LTFU (EOT + 39 months) — Improved56
PF, LTFU (EOT + 39 months) — Worsened27
PF, LTFU (EOT + 39 months) — Stable612
PF, LTFU (EOT + 39 months) — Improved38
RF, LTFU (EOT + 39 months) — Worsened06
RF, LTFU (EOT + 39 months) — Stable712
RF, LTFU (EOT + 39 months) — Improved49
EF, LTFU (EOT + 39 months) — Worsened28
EF, LTFU (EOT + 39 months) — Stable716
EF, LTFU (EOT + 39 months) — Improved23
CF, LTFU (EOT + 39 months) — Worsened412
CF, LTFU (EOT + 39 months) — Stable57
CF, LTFU (EOT + 39 months) — Improved28
SF, LTFU (EOT + 39 months) — Worsened19
SF, LTFU (EOT + 39 months) — Stable412
SF, LTFU (EOT + 39 months) — Improved66
Fatigue, LTFU (EOT + 39 months) — Worsened110
Fatigue, LTFU (EOT + 39 months) — Stable36
Fatigue, LTFU (EOT + 39 months) — Improved711
N/V, LTFU (EOT + 39 months) — Worsened35
N/V, LTFU (EOT + 39 months) — Stable819
N/V, LTFU (EOT + 39 months) — Improved03
Pain, LTFU (EOT + 39 months) — Worsened410
Pain, LTFU (EOT + 39 months) — Stable48
Pain, LTFU (EOT + 39 months) — Improved39
Dyspnoea, LTFU (EOT + 39 months) — Worsened59
Dyspnoea, LTFU (EOT + 39 months) — Stable315
Dyspnoea, LTFU (EOT + 39 months) — Improved33
Insomnia, LTFU (EOT + 39 months) — Worsened55
Insomnia, LTFU (EOT + 39 months) — Stable39
Insomnia, LTFU (EOT + 39 months) — Improved313
AL, LTFU (EOT + 39 months) — Worsened12
AL, LTFU (EOT + 39 months) — Stable720
AL, LTFU (EOT + 39 months) — Improved35
Constipation, LTFU (EOT + 39 months) — Worsened210
Constipation, LTFU (EOT + 39 months) — Stable510
Constipation, LTFU (EOT + 39 months) — Improved47
Diarrhoea, LTFU (EOT + 39 months) — Worsened26
Diarrhoea, LTFU (EOT + 39 months) — Stable816
Diarrhoea, LTFU (EOT + 39 months) — Improved15
FD, LTFU (EOT + 39 months) — Worsened35
FD, LTFU (EOT + 39 months) — Stable618
FD, LTFU (EOT + 39 months) — Improved24
GHS/QoL, LTFU (EOT + 45 months) — Worsened14
GHS/QoL, LTFU (EOT + 45 months) — Stable18
GHS/QoL, LTFU (EOT + 45 months) — Improved23
PF, LTFU (EOT + 45 months) — Worsened13
PF, LTFU (EOT + 45 months) — Stable28
PF, LTFU (EOT + 45 months) — Improved14
RF, LTFU (EOT + 45 months) — Worsened02
RF, LTFU (EOT + 45 months) — Stable48
RF, LTFU (EOT + 45 months) — Improved05
EF, LTFU (EOT + 45 months) — Worsened04
EF, LTFU (EOT + 45 months) — Stable38
EF, LTFU (EOT + 45 months) — Improved13
CF, LTFU (EOT + 45 months) — Worsened04
CF, LTFU (EOT + 45 months) — Stable47
CF, LTFU (EOT + 45 months) — Improved04
SF, LTFU (EOT + 45 months) — Worsened03
SF, LTFU (EOT + 45 months) — Stable28
SF, LTFU (EOT + 45 months) — Improved24
Fatigue, LTFU (EOT + 45 months) — Worsened15
Fatigue, LTFU (EOT + 45 months) — Stable14
Fatigue, LTFU (EOT + 45 months) — Improved26
N/V, LTFU (EOT + 45 months) — Worsened02
N/V, LTFU (EOT + 45 months) — Stable411
N/V, LTFU (EOT + 45 months) — Improved02
Pain, LTFU (EOT + 45 months) — Worsened15
Pain, LTFU (EOT + 45 months) — Stable16
Pain, LTFU (EOT + 45 months) — Improved24
Dyspnoea, LTFU (EOT + 45 months) — Worsened13
Dyspnoea, LTFU (EOT + 45 months) — Stable29
Dyspnoea, LTFU (EOT + 45 months) — Improved13
Insomnia, LTFU (EOT + 45 months) — Worsened25
Insomnia, LTFU (EOT + 45 months) — Stable12
Insomnia, LTFU (EOT + 45 months) — Improved18
AL, LTFU (EOT + 45 months) — Worsened01
AL, LTFU (EOT + 45 months) — Stable212
AL, LTFU (EOT + 45 months) — Improved22
Constipation, LTFU (EOT + 45 months) — Worsened15
Constipation, LTFU (EOT + 45 months) — Stable17
Constipation, LTFU (EOT + 45 months) — Improved23
Diarrhoea, LTFU (EOT + 45 months) — Worsened05
Diarrhoea, LTFU (EOT + 45 months) — Stable37
Diarrhoea, LTFU (EOT + 45 months) — Improved13
FD, LTFU (EOT + 45 months) — Worsened12
FD, LTFU (EOT + 45 months) — Stable111
FD, LTFU (EOT + 45 months) — Improved22
GHS/QoL, LTFU (EOT + 51 months) — Worsened00
GHS/QoL, LTFU (EOT + 51 months) — Stable24
GHS/QoL, LTFU (EOT + 51 months) — Improved01
PF, LTFU (EOT + 51 months) — Worsened11
PF, LTFU (EOT + 51 months) — Stable13
PF, LTFU (EOT + 51 months) — Improved01
RF, LTFU (EOT + 51 months) — Worsened00
RF, LTFU (EOT + 51 months) — Stable12
RF, LTFU (EOT + 51 months) — Improved13
EF, LTFU (EOT + 51 months) — Worsened01
EF, LTFU (EOT + 51 months) — Stable12
EF, LTFU (EOT + 51 months) — Improved12
CF, LTFU (EOT + 51 months) — Worsened01
CF, LTFU (EOT + 51 months) — Stable22
CF, LTFU (EOT + 51 months) — Improved02
SF, LTFU (EOT + 51 months) — Worsened01
SF, LTFU (EOT + 51 months) — Stable13
SF, LTFU (EOT + 51 months) — Improved11
Fatigue, LTFU (EOT + 51 months) — Worsened01
Fatigue, LTFU (EOT + 51 months) — Stable10
Fatigue, LTFU (EOT + 51 months) — Improved14
N/V, LTFU (EOT + 51 months) — Worsened00
N/V, LTFU (EOT + 51 months) — Stable25
N/V, LTFU (EOT + 51 months) — Improved00
Pain, LTFU (EOT + 51 months) — Worsened00
Pain, LTFU (EOT + 51 months) — Stable12
Pain, LTFU (EOT + 51 months) — Improved13
Dyspnoea, LTFU (EOT + 51 months) — Worsened10
Dyspnoea, LTFU (EOT + 51 months) — Stable14
Dyspnoea, LTFU (EOT + 51 months) — Improved01
Insomnia, LTFU (EOT + 51 months) — Worsened01
Insomnia, LTFU (EOT + 51 months) — Stable13
Insomnia, LTFU (EOT + 51 months) — Improved11
AL, LTFU (EOT + 51 months) — Worsened00
AL, LTFU (EOT + 51 months) — Stable14
AL, LTFU (EOT + 51 months) — Improved11
Constipation, LTFU (EOT + 51 months) — Worsened02
Constipation, LTFU (EOT + 51 months) — Stable12
Constipation, LTFU (EOT + 51 months) — Improved11
Diarrhoea, LTFU (EOT + 51 months) — Worsened01
Diarrhoea, LTFU (EOT + 51 months) — Stable13
Diarrhoea, LTFU (EOT + 51 months) — Improved11
FD, LTFU (EOT + 51 months) — Worsened00
FD, LTFU (EOT + 51 months) — Stable03
FD, LTFU (EOT + 51 months) — Improved22
GHS/QoL, LTFU (EOT + 57 months) — Worsened00
GHS/QoL, LTFU (EOT + 57 months) — Stable21
GHS/QoL, LTFU (EOT + 57 months) — Improved00
PF, LTFU (EOT + 57 months) — Worsened10
PF, LTFU (EOT + 57 months) — Stable11
PF, LTFU (EOT + 57 months) — Improved00
RF, LTFU (EOT + 57 months) — Worsened00
RF, LTFU (EOT + 57 months) — Stable20
RF, LTFU (EOT + 57 months) — Improved01
EF, LTFU (EOT + 57 months) — Worsened00
EF, LTFU (EOT + 57 months) — Stable20
EF, LTFU (EOT + 57 months) — Improved01
CF, LTFU (EOT + 57 months) — Worsened00
CF, LTFU (EOT + 57 months) — Stable21
CF, LTFU (EOT + 57 months) — Improved00
SF, LTFU (EOT + 57 months) — Worsened00
SF, LTFU (EOT + 57 months) — Stable11
SF, LTFU (EOT + 57 months) — Improved10
Fatigue, LTFU (EOT + 57 months) — Worsened00
Fatigue, LTFU (EOT + 57 months) — Stable11
Fatigue, LTFU (EOT + 57 months) — Improved10
N/V, LTFU (EOT + 57 months) — Worsened00
N/V, LTFU (EOT + 57 months) — Stable21
N/V, LTFU (EOT + 57 months) — Improved00
Pain, LTFU (EOT + 57 months) — Worsened00
Pain, LTFU (EOT + 57 months) — Stable10
Pain, LTFU (EOT + 57 months) — Improved11
Dyspnoea, LTFU (EOT + 57 months) — Worsened10
Dyspnoea, LTFU (EOT + 57 months) — Stable11
Dyspnoea, LTFU (EOT + 57 months) — Improved00
Insomnia, LTFU (EOT + 57 months) — Worsened00
Insomnia, LTFU (EOT + 57 months) — Stable11
Insomnia, LTFU (EOT + 57 months) — Improved10
AL, LTFU (EOT + 57 months) — Worsened00
AL, LTFU (EOT + 57 months) — Stable11
AL, LTFU (EOT + 57 months) — Improved10
Constipation, LTFU (EOT + 57 months) — Worsened00
Constipation, LTFU (EOT + 57 months) — Stable10
Constipation, LTFU (EOT + 57 months) — Improved11
Diarrhoea, LTFU (EOT + 57 months) — Worsened00
Diarrhoea, LTFU (EOT + 57 months) — Stable10
Diarrhoea, LTFU (EOT + 57 months) — Improved11
FD, LTFU (EOT + 57 months) — Worsened00
FD, LTFU (EOT + 57 months) — Stable01
FD, LTFU (EOT + 57 months) — Improved20
GHS/QoL, LTFU (EOT + 63 months) — Worsened00
GHS/QoL, LTFU (EOT + 63 months) — Stable10
GHS/QoL, LTFU (EOT + 63 months) — Improved00
PF, LTFU (EOT + 63 months) — Worsened00
PF, LTFU (EOT + 63 months) — Stable10
PF, LTFU (EOT + 63 months) — Improved00
RF, LTFU (EOT + 63 months) — Worsened00
RF, LTFU (EOT + 63 months) — Stable10
RF, LTFU (EOT + 63 months) — Improved00
EF, LTFU (EOT + 63 months) — Worsened00
EF, LTFU (EOT + 63 months) — Stable10
EF, LTFU (EOT + 63 months) — Improved00
CF, LTFU (EOT + 63 months) — Worsened00
CF, LTFU (EOT + 63 months) — Stable10
CF, LTFU (EOT + 63 months) — Improved00
SF, LTFU (EOT + 63 months) — Worsened00
SF, LTFU (EOT + 63 months) — Stable10
SF, LTFU (EOT + 63 months) — Improved00
Fatigue, LTFU (EOT + 63 months) — Worsened00
Fatigue, LTFU (EOT + 63 months) — Stable10
Fatigue, LTFU (EOT + 63 months) — Improved00
N/V, LTFU (EOT + 63 months) — Worsened00
N/V, LTFU (EOT + 63 months) — Stable10
N/V, LTFU (EOT + 63 months) — Improved00
Pain, LTFU (EOT + 63 months) — Worsened00
Pain, LTFU (EOT + 63 months) — Stable10
Pain, LTFU (EOT + 63 months) — Improved00
Dyspnoea, LTFU (EOT + 63 months) — Worsened00
Dyspnoea, LTFU (EOT + 63 months) — Stable10
Dyspnoea, LTFU (EOT + 63 months) — Improved00
Insomnia, LTFU (EOT + 63 months) — Worsened00
Insomnia, LTFU (EOT + 63 months) — Stable10
Insomnia, LTFU (EOT + 63 months) — Improved00
AL, LTFU (EOT + 63 months) — Worsened00
AL, LTFU (EOT + 63 months) — Stable10
AL, LTFU (EOT + 63 months) — Improved00
Constipation, LTFU (EOT + 63 months) — Worsened00
Constipation, LTFU (EOT + 63 months) — Stable00
Constipation, LTFU (EOT + 63 months) — Improved10
Diarrhoea, LTFU (EOT + 63 months) — Worsened00
Diarrhoea, LTFU (EOT + 63 months) — Stable10
Diarrhoea, LTFU (EOT + 63 months) — Improved00
FD, LTFU (EOT + 63 months) — Worsened00
FD, LTFU (EOT + 63 months) — Stable00
FD, LTFU (EOT + 63 months) — Improved10
SecondaryNumber of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire

The EORTC QLQ-OV28 supplements the QLQ-C30. It includes three functional scales (body image (BI), sexuality (S), attitude to disease/treatment(ATD)) and five symptom scales/items (abdominal/GI symptoms (AS), peripheral neuropathy (PN), hormonal/menopausal symptoms (MS), other chemotherapy side effects (CSE), and hair loss (HS)). Participants responded on a scale of 1-4 (1=not at all, 2=a little, 3=quite a bit, 4=very much). Higher scores represent better functioning (better quality of life). For functional scales: improved (worsened) is defined as \>=10 points increase (decrease) from baseline. For symptom scales: improved (worsened) is defined as \>=10 points decrease (increase) from baseline. Baseline is defined as the latest, non-missing collected value, excluding end of treatment, safety follow-up, long term follow-up visits records and unscheduled visits after end of treatment.

Time frame:
Day1 of Chemo Cycles 2(baseline), 4&6; Day1 of Maintenance Cycles 1,2,3,6,9,12,15,17,23,29,35,41,47,53,59,65,71,77,83,89; EOT visit up to a maximum of 63 months; LTFU visit up to a maximum of 69 months(including SFU visit up to a maximum of 61 months)
Reported as:
Count of participants · Participants
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
ParticipantsPaclitaxel + Carboplatin + Dostarlimab Pbo +/- Bev, Then Niraparib+Dostarlimab Pbo +/- Bev (Arm2)Paclitaxel + Carboplatin + Dostarlimab +/- Bev, Then Niraparib+Dostarlimab +/- Bev (Arm3)
BI, Cycle 4 Chemotherapy — Worsened89214
BI, Cycle 4 Chemotherapy — Stable108189
BI, Cycle 4 Chemotherapy — Improved73131
S, Cycle 4 Chemotherapy — Worsened3059
S, Cycle 4 Chemotherapy — Stable188390
S, Cycle 4 Chemotherapy — Improved5177
ATD, Cycle 4 Chemotherapy — Worsened103205
ATD, Cycle 4 Chemotherapy — Stable91148
ATD, Cycle 4 Chemotherapy — Improved76181
AS, Cycle 4 Chemotherapy — Worsened4081
AS, Cycle 4 Chemotherapy — Stable166325
AS, Cycle 4 Chemotherapy — Improved70129
PN, Cycle 4 Chemotherapy — Worsened151316
PN, Cycle 4 Chemotherapy — Stable68135
PN, Cycle 4 Chemotherapy — Improved5784
MS, Cycle 4 Chemotherapy — Worsened68153
MS, Cycle 4 Chemotherapy — Stable135255
MS, Cycle 4 Chemotherapy — Improved73127
CSE, Cycle 4 Chemotherapy — Worsened88168
CSE, Cycle 4 Chemotherapy — Stable145278
CSE, Cycle 4 Chemotherapy — Improved4389
HS, Cycle 4 Chemotherapy — Worsened92176
HS, Cycle 4 Chemotherapy — Stable81139
HS, Cycle 4 Chemotherapy — Improved100219
BI, Cycle 6 Chemotherapy — Worsened99216
BI, Cycle 6 Chemotherapy — Stable97168
BI, Cycle 6 Chemotherapy — Improved70148
S, Cycle 6 Chemotherapy — Worsened2971
S, Cycle 6 Chemotherapy — Stable184368
S, Cycle 6 Chemotherapy — Improved4886
ATD, Cycle 6 Chemotherapy — Worsened87218
ATD, Cycle 6 Chemotherapy — Stable81132
ATD, Cycle 6 Chemotherapy — Improved97182
AS, Cycle 6 Chemotherapy — Worsened3266
AS, Cycle 6 Chemotherapy — Stable148312
AS, Cycle 6 Chemotherapy — Improved87156
PN, Cycle 6 Chemotherapy — Worsened175371
PN, Cycle 6 Chemotherapy — Stable5099
PN, Cycle 6 Chemotherapy — Improved4263
MS, Cycle 6 Chemotherapy — Worsened71161
MS, Cycle 6 Chemotherapy — Stable113240
MS, Cycle 6 Chemotherapy — Improved83132
CSE, Cycle 6 Chemotherapy — Worsened77173
CSE, Cycle 6 Chemotherapy — Stable144279
CSE, Cycle 6 Chemotherapy — Improved4680
HS, Cycle 6 Chemotherapy — Worsened106181
HS, Cycle 6 Chemotherapy — Stable60121
HS, Cycle 6 Chemotherapy — Improved100230
BI, Cycle 1 Maintenance — Worsened95187
BI, Cycle 1 Maintenance — Stable92165
BI, Cycle 1 Maintenance — Improved75142
S, Cycle 1 Maintenance — Worsened2963
S, Cycle 1 Maintenance — Stable172337
S, Cycle 1 Maintenance — Improved5385
ATD, Cycle 1 Maintenance — Worsened104181
ATD, Cycle 1 Maintenance — Stable73143
ATD, Cycle 1 Maintenance — Improved85170
AS, Cycle 1 Maintenance — Worsened2555
AS, Cycle 1 Maintenance — Stable152284
AS, Cycle 1 Maintenance — Improved85157
PN, Cycle 1 Maintenance — Worsened173358
PN, Cycle 1 Maintenance — Stable4973
PN, Cycle 1 Maintenance — Improved4064
MS, Cycle 1 Maintenance — Worsened68127
MS, Cycle 1 Maintenance — Stable115239
MS, Cycle 1 Maintenance — Improved79130
CSE, Cycle 1 Maintenance — Worsened66162
CSE, Cycle 1 Maintenance — Stable151235
CSE, Cycle 1 Maintenance — Improved4598
HS, Cycle 1 Maintenance — Worsened89145
HS, Cycle 1 Maintenance — Stable56117
HS, Cycle 1 Maintenance — Improved115232
BI, Cycle 2 Maintenance — Worsened74162
BI, Cycle 2 Maintenance — Stable85143
BI, Cycle 2 Maintenance — Improved68124
S, Cycle 2 Maintenance — Worsened1653
S, Cycle 2 Maintenance — Stable166290
S, Cycle 2 Maintenance — Improved3874
ATD, Cycle 2 Maintenance — Worsened75156
ATD, Cycle 2 Maintenance — Stable54103
ATD, Cycle 2 Maintenance — Improved98169
AS, Cycle 2 Maintenance — Worsened1935
AS, Cycle 2 Maintenance — Stable127260
AS, Cycle 2 Maintenance — Improved82136
PN, Cycle 2 Maintenance — Worsened128277
PN, Cycle 2 Maintenance — Stable5779
PN, Cycle 2 Maintenance — Improved4374
MS, Cycle 2 Maintenance — Worsened52129
MS, Cycle 2 Maintenance — Stable106186
MS, Cycle 2 Maintenance — Improved70115
CSE, Cycle 2 Maintenance — Worsened54115
CSE, Cycle 2 Maintenance — Stable125229
CSE, Cycle 2 Maintenance — Improved4986
HS, Cycle 2 Maintenance — Worsened4885
HS, Cycle 2 Maintenance — Stable57100
HS, Cycle 2 Maintenance — Improved119243
BI, Cycle 3 Maintenance — Worsened70159
BI, Cycle 3 Maintenance — Stable88147
BI, Cycle 3 Maintenance — Improved74135
S, Cycle 3 Maintenance — Worsened2455
S, Cycle 3 Maintenance — Stable161291
S, Cycle 3 Maintenance — Improved4178
ATD, Cycle 3 Maintenance — Worsened71161
ATD, Cycle 3 Maintenance — Stable55109
ATD, Cycle 3 Maintenance — Improved106171
AS, Cycle 3 Maintenance — Worsened3856
AS, Cycle 3 Maintenance — Stable123246
AS, Cycle 3 Maintenance — Improved72140
PN, Cycle 3 Maintenance — Worsened129285
PN, Cycle 3 Maintenance — Stable5391
PN, Cycle 3 Maintenance — Improved5066
MS, Cycle 3 Maintenance — Worsened69144
MS, Cycle 3 Maintenance — Stable92193
MS, Cycle 3 Maintenance — Improved71105
CSE, Cycle 3 Maintenance — Worsened54110
CSE, Cycle 3 Maintenance — Stable118242
CSE, Cycle 3 Maintenance — Improved6090
HS, Cycle 3 Maintenance — Worsened3254
HS, Cycle 3 Maintenance — Stable6696
HS, Cycle 3 Maintenance — Improved134290
BI, Cycle 6 Maintenance — Worsened54126
BI, Cycle 6 Maintenance — Stable72132
BI, Cycle 6 Maintenance — Improved69139
S, Cycle 6 Maintenance — Worsened1645
S, Cycle 6 Maintenance — Stable121242
S, Cycle 6 Maintenance — Improved5395
ATD, Cycle 6 Maintenance9 — Worsened54117
ATD, Cycle 6 Maintenance9 — Stable44101
ATD, Cycle 6 Maintenance9 — Improved97179
AS, Cycle 6 Maintenance — Worsened2249
AS, Cycle 6 Maintenance — Stable106222
AS, Cycle 6 Maintenance — Improved70128
PN, Cycle 6 Maintenance — Worsened108234
PN, Cycle 6 Maintenance — Stable4389
PN, Cycle 6 Maintenance — Improved4775
MS, Cycle 6 Maintenance — Worsened53127
MS, Cycle 6 Maintenance — Stable85164
MS, Cycle 6 Maintenance — Improved60107
CSE, Cycle 6 Maintenance — Worsened37102
CSE, Cycle 6 Maintenance — Stable111200
CSE, Cycle 6 Maintenance — Improved5096
HS, Cycle 6 Maintenance — Worsened1323
HS, Cycle 6 Maintenance — Stable5892
HS, Cycle 6 Maintenance — Improved125282
BI, Cycle 9 Maintenance — Worsened5199
BI, Cycle 9 Maintenance — Stable59130
BI, Cycle 9 Maintenance — Improved75130
S, Cycle 9 Maintenance — Worsened1940
S, Cycle 9 Maintenance — Stable109201
S, Cycle 9 Maintenance — Improved51103
ATD, Cycle 9 Maintenance — Worsened4789
ATD, Cycle 9 Maintenance — Stable3986
ATD, Cycle 9 Maintenance — Improved99184
AS, Cycle 9 Maintenance — Worsened2238
AS, Cycle 9 Maintenance — Stable103198
AS, Cycle 9 Maintenance — Improved61125
PN, Cycle 9 Maintenance — Worsened91206
PN, Cycle 9 Maintenance — Stable5275
PN, Cycle 9 Maintenance — Improved4379
MS, Cycle 9 Maintenance — Worsened5196
MS, Cycle 9 Maintenance — Stable67158
MS, Cycle 9 Maintenance — Improved68106
CSE, Cycle 9 Maintenance — Worsened3981
CSE, Cycle 9 Maintenance — Stable101193
CSE, Cycle 9 Maintenance — Improved4686
HS, Cycle 9 Maintenance — Worsened717
HS, Cycle 9 Maintenance — Stable5274
HS, Cycle 9 Maintenance — Improved126268
BI, Cycle 12 Maintenance — Worsened3279
BI, Cycle 12 Maintenance — Stable5799
BI, Cycle 12 Maintenance — Improved67130
S, Cycle 12 Maintenance — Worsened1430
S, Cycle 12 Maintenance — Stable86178
S, Cycle 12 Maintenance — Improved5185
ATD, Cycle 12 Maintenance — Worsened3583
ATD, Cycle 12 Maintenance — Stable3959
ATD, Cycle 12 Maintenance — Improved82166
AS, Cycle 12 Maintenance — Worsened1649
AS, Cycle 12 Maintenance — Stable90166
AS, Cycle 12 Maintenance — Improved5293
PN, Cycle 12 Maintenance — Worsened68164
PN, Cycle 12 Maintenance — Stable4673
PN, Cycle 12 Maintenance — Improved4471
MS, Cycle 12 Maintenance — Worsened4491
MS, Cycle 12 Maintenance — Stable59138
MS, Cycle 12 Maintenance — Improved5579
CSE, Cycle 12 Maintenance — Worsened2566
CSE, Cycle 12 Maintenance — Stable95164
CSE, Cycle 12 Maintenance — Improved3878
HS, Cycle 12 Maintenance — Worsened56
HS, Cycle 12 Maintenance — Stable4468
HS, Cycle 12 Maintenance — Improved108231
BI, Cycle 15 Maintenance — Worsened4073
BI, Cycle 15 Maintenance — Stable5492
BI, Cycle 15 Maintenance — Improved55114
S, Cycle 15 Maintenance — Worsened1833
S, Cycle 15 Maintenance — Stable82162
S, Cycle 15 Maintenance — Improved4468
ATD, Cycle 15 Maintenance — Worsened2659
ATD, Cycle 15 Maintenance — Stable3569
ATD, Cycle 15 Maintenance — Improved88151
AS, Cycle 15 Maintenance — Worsened2230
AS, Cycle 15 Maintenance — Stable86154
AS, Cycle 15 Maintenance — Improved4297
PN, Cycle 15 Maintenance — Worsened66147
PN, Cycle 15 Maintenance — Stable4259
PN, Cycle 15 Maintenance — Improved4272
MS, Cycle 15 Maintenance — Worsened4180
MS, Cycle 15 Maintenance — Stable62116
MS, Cycle 15 Maintenance — Improved4783
CSE, Cycle 15 Maintenance — Worsened3060
CSE, Cycle 15 Maintenance — Stable80144
CSE, Cycle 15 Maintenance — Improved4074
HS, Cycle 15 Maintenance — Worsened76
HS, Cycle 15 Maintenance — Stable4059
HS, Cycle 15 Maintenance — Improved100213
BI, Cycle 17 Maintenance — Worsened1015
BI, Cycle 17 Maintenance — Stable1332
BI, Cycle 17 Maintenance — Improved1635
S, Cycle 17 Maintenance — Worsened410
S, Cycle 17 Maintenance — Stable1842
S, Cycle 17 Maintenance — Improved1627
ATD, Cycle 17 Maintenance — Worsened816
ATD, Cycle 17 Maintenance — Stable617
ATD, Cycle 17 Maintenance — Improved2548
AS, Cycle 17 Maintenance — Worsened79
AS, Cycle 17 Maintenance — Stable1938
AS, Cycle 17 Maintenance — Improved1436
PN, Cycle 17 Maintenance — Worsened1945
PN, Cycle 17 Maintenance — Stable719
PN, Cycle 17 Maintenance — Improved1419
MS, Cycle 17 Maintenance — Worsened1025
MS, Cycle 17 Maintenance — Stable1131
MS, Cycle 17 Maintenance — Improved1927
CSE, Cycle 17 Maintenance — Worsened720
CSE, Cycle 17 Maintenance — Stable2038
CSE, Cycle 17 Maintenance — Improved1325
HS, Cycle 17 Maintenance — Worsened12
HS, Cycle 17 Maintenance — Stable1014
HS, Cycle 17 Maintenance — Improved2866
BI, Cycle 23 Maintenance — Worsened925
BI, Cycle 23 Maintenance — Stable2037
BI, Cycle 23 Maintenance — Improved2637
S, Cycle 23 Maintenance — Worsened49
S, Cycle 23 Maintenance — Stable3652
S, Cycle 23 Maintenance — Improved1431
ATD, Cycle 23 Maintenance — Worsened821
ATD, Cycle 23 Maintenance — Stable1520
ATD, Cycle 23 Maintenance — Improved3257
AS, Cycle 23 Maintenance — Worsened812
AS, Cycle 23 Maintenance — Stable3452
AS, Cycle 23 Maintenance — Improved1435
PN, Cycle 23 Maintenance — Worsened2050
PN, Cycle 23 Maintenance — Stable1817
PN, Cycle 23 Maintenance — Improved1832
MS, Cycle 23 Maintenance — Worsened1828
MS, Cycle 23 Maintenance — Stable2546
MS, Cycle 23 Maintenance — Improved1326
CSE, Cycle 23 Maintenance — Worsened921
CSE, Cycle 23 Maintenance — Stable2848
CSE, Cycle 23 Maintenance — Improved1930
HS, Cycle 23 Maintenance — Worsened46
HS, Cycle 23 Maintenance — Stable1717
HS, Cycle 23 Maintenance — Improved3574
BI, Cycle 29 Maintenance — Worsened1326
BI, Cycle 29 Maintenance — Stable1829
BI, Cycle 29 Maintenance — Improved2038
S, Cycle 29 Maintenance — Worsened511
S, Cycle 29 Maintenance — Stable2546
S, Cycle 29 Maintenance — Improved1928
ATD, Cycle 29 Maintenance — Worsened818
ATD, Cycle 29 Maintenance — Stable1121
ATD, Cycle 29 Maintenance — Improved3255
AS, Cycle 29 Maintenance — Worsened914
AS, Cycle 29 Maintenance — Stable3052
AS, Cycle 29 Maintenance — Improved1228
PN, Cycle 29 Maintenance — Worsened1748
PN, Cycle 29 Maintenance — Stable1620
PN, Cycle 29 Maintenance — Improved1726
MS, Cycle 29 Maintenance — Worsened1424
MS, Cycle 29 Maintenance — Stable1645
MS, Cycle 29 Maintenance — Improved2025
CSE, Cycle 29 Maintenance — Worsened719
CSE, Cycle 29 Maintenance — Stable3054
CSE, Cycle 29 Maintenance — Improved1321
HS, Cycle 29 Maintenance — Worsened16
HS, Cycle 29 Maintenance — Stable1419
HS, Cycle 29 Maintenance — Improved3568
BI, Cycle 35 Maintenance — Worsened1319
BI, Cycle 35 Maintenance — Stable1135
BI, Cycle 35 Maintenance — Improved2131
S, Cycle 35 Maintenance — Worsened512
S, Cycle 35 Maintenance — Stable2647
S, Cycle 35 Maintenance — Improved1321
ATD, Cycle 35 Maintenance — Worsened920
ATD, Cycle 35 Maintenance — Stable1114
ATD, Cycle 35 Maintenance — Improved2550
AS, Cycle 35 Maintenance — Worsened615
AS, Cycle 35 Maintenance — Stable2548
AS, Cycle 35 Maintenance — Improved1323
PN, Cycle 35 Maintenance — Worsened1433
PN, Cycle 35 Maintenance — Stable1928
PN, Cycle 35 Maintenance — Improved1225
MS, Cycle 35 Maintenance — Worsened926
MS, Cycle 35 Maintenance — Stable1738
MS, Cycle 35 Maintenance — Improved1922
CSE, Cycle 35 Maintenance — Worsened1018
CSE, Cycle 35 Maintenance — Stable2442
CSE, Cycle 35 Maintenance — Improved1126
HS, Cycle 35 Maintenance — Worsened26
HS, Cycle 35 Maintenance — Stable1514
HS, Cycle 35 Maintenance — Improved2864
BI, Cycle 41 Maintenance — Worsened2330
BI, Cycle 41 Maintenance — Stable1536
BI, Cycle 41 Maintenance — Improved1938
S, Cycle 41 Maintenance — Worsened614
S, Cycle 41 Maintenance — Stable3053
S, Cycle 41 Maintenance — Improved2134
ATD, Cycle 41 Maintenance — Worsened1026
ATD, Cycle 41 Maintenance — Stable1321
ATD, Cycle 41 Maintenance — Improved3457
AS, Cycle 41 Maintenance — Worsened1116
AS, Cycle 41 Maintenance — Stable3152
AS, Cycle 41 Maintenance — Improved1536
PN, Cycle 41 Maintenance — Worsened2552
PN, Cycle 41 Maintenance — Stable1927
PN, Cycle 41 Maintenance — Improved1224
MS, Cycle 41 Maintenance — Worsened1829
MS, Cycle 41 Maintenance — Stable1951
MS, Cycle 41 Maintenance — Improved1923
CSE, Cycle 41 Maintenance — Worsened1520
CSE, Cycle 41 Maintenance — Stable2650
CSE, Cycle 41 Maintenance — Improved1533
HS, Cycle 41 Maintenance — Worsened39
HS, Cycle 41 Maintenance — Stable1717
HS, Cycle 41 Maintenance — Improved3777
BI, Cycle 47 Maintenance — Worsened1419
BI, Cycle 47 Maintenance — Stable1834
BI, Cycle 47 Maintenance — Improved1533
S, Cycle 47 Maintenance — Worsened66
S, Cycle 47 Maintenance — Stable2146
S, Cycle 47 Maintenance — Improved2027
ATD, Cycle 47 Maintenance — Worsened719
ATD, Cycle 47 Maintenance — Stable919
ATD, Cycle 47 Maintenance — Improved3147
AS, Cycle 47 Maintenance — Worsened1016
AS, Cycle 47 Maintenance — Stable2844
AS, Cycle 47 Maintenance — Improved926
PN, Cycle 47 Maintenance — Worsened2140
PN, Cycle 47 Maintenance — Stable1425
PN, Cycle 47 Maintenance — Improved1221
MS, Cycle 47 Maintenance — Worsened1224
MS, Cycle 47 Maintenance — Stable1943
MS, Cycle 47 Maintenance — Improved1619
CSE, Cycle 47 Maintenance — Worsened918
CSE, Cycle 47 Maintenance — Stable2944
CSE, Cycle 47 Maintenance — Improved924
HS, Cycle 47 Maintenance — Worsened56
HS, Cycle 47 Maintenance — Stable1216
HS, Cycle 47 Maintenance — Improved3060
BI, Cycle 53 Maintenance — Worsened1014
BI, Cycle 53 Maintenance — Stable820
BI, Cycle 53 Maintenance — Improved820
S, Cycle 53 Maintenance — Worsened45
S, Cycle 53 Maintenance — Stable1132
S, Cycle 53 Maintenance — Improved1114
ATD, Cycle 53 Maintenance — Worsened312
ATD, Cycle 53 Maintenance — Stable59
ATD, Cycle 53 Maintenance — Improved1833
AS, Cycle 53 Maintenance — Worsened511
AS, Cycle 53 Maintenance — Stable1533
AS, Cycle 53 Maintenance — Improved610
PN, Cycle 53 Maintenance — Worsened727
PN, Cycle 53 Maintenance — Stable1315
PN, Cycle 53 Maintenance — Improved611
MS, Cycle 53 Maintenance — Worsened724
MS, Cycle 53 Maintenance — Stable918
MS, Cycle 53 Maintenance — Improved1011
CSE, Cycle 53 Maintenance — Worsened411
CSE, Cycle 53 Maintenance — Stable1433
CSE, Cycle 53 Maintenance — Improved89
HS, Cycle 53 Maintenance — Worsened42
HS, Cycle 53 Maintenance — Stable811
HS, Cycle 53 Maintenance — Improved1441
BI, Cycle 59 Maintenance — Worsened67
BI, Cycle 59 Maintenance — Stable611
BI, Cycle 59 Maintenance — Improved617
S, Cycle 59 Maintenance — Worsened13
S, Cycle 59 Maintenance — Stable920
S, Cycle 59 Maintenance — Improved811
ATD, Cycle 59 Maintenance — Worsened34
ATD, Cycle 59 Maintenance — Stable56
ATD, Cycle 59 Maintenance — Improved1025
AS, Cycle 59 Maintenance — Worsened36
AS, Cycle 59 Maintenance — Stable1220
AS, Cycle 59 Maintenance — Improved39
PN, Cycle 59 Maintenance — Worsened715
PN, Cycle 59 Maintenance — Stable612
PN, Cycle 59 Maintenance — Improved58
MS, Cycle 59 Maintenance — Worsened59
MS, Cycle 59 Maintenance — Stable617
MS, Cycle 59 Maintenance — Improved79
CSE, Cycle 59 Maintenance — Worsened36
CSE, Cycle 59 Maintenance — Stable1022
CSE, Cycle 59 Maintenance — Improved57
HS, Cycle 59 Maintenance — Worsened43
HS, Cycle 59 Maintenance — Stable46
HS, Cycle 59 Maintenance — Improved1026
BI, Cycle 65 Maintenance — Worsened34
BI, Cycle 65 Maintenance — Stable410
BI, Cycle 65 Maintenance — Improved511
S, Cycle 65 Maintenance — Worsened23
S, Cycle 65 Maintenance — Stable512
S, Cycle 65 Maintenance — Improved59
ATD, Cycle 65 Maintenance — Worsened15
ATD, Cycle 65 Maintenance — Stable55
ATD, Cycle 65 Maintenance — Improved615
AS, Cycle 65 Maintenance — Worsened24
AS, Cycle 65 Maintenance — Stable917
AS, Cycle 65 Maintenance — Improved14
PN, Cycle 65 Maintenance — Worsened59
PN, Cycle 65 Maintenance — Stable59
PN, Cycle 65 Maintenance — Improved27
MS, Cycle 65 Maintenance — Worsened36
MS, Cycle 65 Maintenance — Stable314
MS, Cycle 65 Maintenance — Improved65
CSE, Cycle 65 Maintenance — Worsened25
CSE, Cycle 65 Maintenance — Stable914
CSE, Cycle 65 Maintenance — Improved16
HS, Cycle 65 Maintenance — Worsened42
HS, Cycle 65 Maintenance — Stable43
HS, Cycle 65 Maintenance — Improved420
BI, Cycle 71 Maintenance — Worsened13
BI, Cycle 71 Maintenance — Stable16
BI, Cycle 71 Maintenance — Improved64
S, Cycle 71 Maintenance — Worsened20
S, Cycle 71 Maintenance — Stable410
S, Cycle 71 Maintenance — Improved13
ATD, Cycle 71 Maintenance — Worsened12
ATD, Cycle 71 Maintenance — Stable14
ATD, Cycle 71 Maintenance — Improved67
AS, Cycle 71 Maintenance — Worsened31
AS, Cycle 71 Maintenance — Stable411
AS, Cycle 71 Maintenance — Improved11
PN, Cycle 71 Maintenance — Worsened26
PN, Cycle 71 Maintenance — Stable44
PN, Cycle 71 Maintenance — Improved13
MS, Cycle 71 Maintenance — Worsened13
MS, Cycle 71 Maintenance — Stable17
MS, Cycle 71 Maintenance — Improved53
CSE, Cycle 71 Maintenance — Worsened11
CSE, Cycle 71 Maintenance — Stable510
CSE, Cycle 71 Maintenance — Improved12
HS, Cycle 71 Maintenance — Worsened30
HS, Cycle 71 Maintenance — Stable25
HS, Cycle 71 Maintenance — Improved38
BI, Cycle 77 Maintenance — Worsened13
BI, Cycle 77 Maintenance — Stable12
BI, Cycle 77 Maintenance — Improved26
S, Cycle 77 Maintenance — Worsened12
S, Cycle 77 Maintenance — Stable24
S, Cycle 77 Maintenance — Improved05
ATD, Cycle 77 Maintenance — Worsened02
ATD, Cycle 77 Maintenance — Stable11
ATD, Cycle 77 Maintenance — Improved38
AS, Cycle 77 Maintenance — Worsened02
AS, Cycle 77 Maintenance — Stable26
AS, Cycle 77 Maintenance — Improved23
PN, Cycle 77 Maintenance — Worsened26
PN, Cycle 77 Maintenance — Stable11
PN, Cycle 77 Maintenance — Improved14
MS, Cycle 77 Maintenance — Worsened05
MS, Cycle 77 Maintenance — Stable04
MS, Cycle 77 Maintenance — Improved42
CSE, Cycle 77 Maintenance — Worsened11
CSE, Cycle 77 Maintenance — Stable28
CSE, Cycle 77 Maintenance — Improved12
HS, Cycle 77 Maintenance — Worsened03
HS, Cycle 77 Maintenance — Stable21
HS, Cycle 77 Maintenance — Improved27
BI, Cycle 83 Maintenance — Worsened11
BI, Cycle 83 Maintenance — Stable00
BI, Cycle 83 Maintenance — Improved24
S, Cycle 83 Maintenance — Worsened11
S, Cycle 83 Maintenance — Stable10
S, Cycle 83 Maintenance — Improved14
ATD, Cycle 83 Maintenance — Worsened00
ATD, Cycle 83 Maintenance — Stable10
ATD, Cycle 83 Maintenance — Improved25
AS, Cycle 83 Maintenance — Worsened00
AS, Cycle 83 Maintenance — Stable24
AS, Cycle 83 Maintenance — Improved11
PN, Cycle 83 Maintenance — Worsened01
PN, Cycle 83 Maintenance — Stable10
PN, Cycle 83 Maintenance — Improved24
MS, Cycle 83 Maintenance — Worsened01
MS, Cycle 83 Maintenance — Stable04
MS, Cycle 83 Maintenance — Improved30
CSE, Cycle 83 Maintenance — Worsened10
CSE, Cycle 83 Maintenance — Stable12
CSE, Cycle 83 Maintenance — Improved13
HS, Cycle 83 Maintenance — Worsened01
HS, Cycle 83 Maintenance — Stable20
HS, Cycle 83 Maintenance — Improved14
BI, Cycle 89 Maintenance — Worsened00
BI, Cycle 89 Maintenance — Stable00
BI, Cycle 89 Maintenance — Improved02
S, Cycle 89 Maintenance — Worsened00
S, Cycle 89 Maintenance — Stable00
S, Cycle 89 Maintenance — Improved01
ATD, Cycle 89 Maintenance — Worsened00
ATD, Cycle 89 Maintenance — Stable00
ATD, Cycle 89 Maintenance — Improved02
AS, Cycle 89 Maintenance — Worsened00
AS, Cycle 89 Maintenance — Stable00
AS, Cycle 89 Maintenance — Improved02
PN, Cycle 89 Maintenance — Worsened00
PN, Cycle 89 Maintenance — Stable01
PN, Cycle 89 Maintenance — Improved01
MS, Cycle 89 Maintenance — Worsened00
MS, Cycle 89 Maintenance — Stable02
MS, Cycle 89 Maintenance — Improved00
CSE, Cycle 89 Maintenance — Worsened00
CSE, Cycle 89 Maintenance — Stable00
CSE, Cycle 89 Maintenance — Improved02
HS, Cycle 89 Maintenance — Worsened00
HS, Cycle 89 Maintenance — Stable00
HS, Cycle 89 Maintenance — Improved02
BI, End of treatment — Worsened4594
BI, End of treatment — Stable68109
BI, End of treatment — Improved68134
S, End of treatment — Worsened2152
S, End of treatment — Stable122206
S, End of treatment — Improved3366
ATD, End of treatment — Worsened65124
ATD, End of treatment — Stable4372
ATD, End of treatment — Improved72142
AS, End of treatment — Worsened4559
AS, End of treatment — Stable90186
AS, End of treatment — Improved4696
PN, End of treatment — Worsened79171
PN, End of treatment — Stable5283
PN, End of treatment — Improved5085
MS, End of treatment — Worsened4297
MS, End of treatment — Stable83149
MS, End of treatment — Improved5694
CSE, End of treatment — Worsened3575
CSE, End of treatment — Stable94180
CSE, End of treatment — Improved5285
HS, End of treatment — Worsened1324
HS, End of treatment — Stable4576
HS, End of treatment — Improved122240
BI, Safety Follow-up — Worsened4294
BI, Safety Follow-up — Stable4784
BI, Safety Follow-up — Improved52102
S, Safety Follow-up — Worsened1642
S, Safety Follow-up — Stable90175
S, Safety Follow-up — Improved2855
ATD, Safety Follow-up — Worsened50111
ATD, Safety Follow-up — Stable3267
ATD, Safety Follow-up — Improved59103
AS, Safety Follow-up — Worsened2255
AS, Safety Follow-up — Stable78152
AS, Safety Follow-up — Improved4375
PN, Safety Follow-up — Worsened72151
PN, Safety Follow-up — Stable3670
PN, Safety Follow-up — Improved3561
MS, Safety Follow-up — Worsened2983
MS, Safety Follow-up — Stable67130
MS, Safety Follow-up — Improved4769
CSE, Safety Follow-up — Worsened2966
CSE, Safety Follow-up — Stable77139
CSE, Safety Follow-up — Improved3777
HS, Safety Follow-up — Worsened1526
HS, Safety Follow-up — Stable3752
HS, Safety Follow-up — Improved90203
BI, LTFU (EOT + 3 months) — Worsened4779
BI, LTFU (EOT + 3 months) — Stable4683
BI, LTFU (EOT + 3 months) — Improved4181
S, LTFU (EOT + 3 months) — Worsened2435
S, LTFU (EOT + 3 months) — Stable79157
S, LTFU (EOT + 3 months) — Improved2542
ATD, LTFU (EOT + 3 months) — Worsened4688
ATD, LTFU (EOT + 3 months) — Stable3347
ATD, LTFU (EOT + 3 months) — Improved55108
AS, LTFU (EOT + 3 months) — Worsened2344
AS, LTFU (EOT + 3 months) — Stable68132
AS, LTFU (EOT + 3 months) — Improved4367
PN, LTFU (EOT + 3 months) — Worsened63135
PN, LTFU (EOT + 3 months) — Stable3956
PN, LTFU (EOT + 3 months) — Improved3252
MS, LTFU (EOT + 3 months) — Worsened2756
MS, LTFU (EOT + 3 months) — Stable52108
MS, LTFU (EOT + 3 months) — Improved5578
CSE, LTFU (EOT + 3 months) — Worsened3067
CSE, LTFU (EOT + 3 months) — Stable79116
CSE, LTFU (EOT + 3 months) — Improved2560
HS, LTFU (EOT + 3 months) — Worsened1725
HS, LTFU (EOT + 3 months) — Stable2942
HS, LTFU (EOT + 3 months) — Improved86173
BI, LTFU (EOT + 9 months) — Worsened3656
BI, LTFU (EOT + 9 months) — Stable3756
BI, LTFU (EOT + 9 months) — Improved3468
S, LTFU (EOT + 9 months) — Worsened1331
S, LTFU (EOT + 9 months) — Stable74110
S, LTFU (EOT + 9 months) — Improved1931
ATD, LTFU (EOT + 9 months) — Worsened4267
ATD, LTFU (EOT + 9 months) — Stable1728
ATD, LTFU (EOT + 9 months) — Improved4784
AS, LTFU (EOT + 9 months) — Worsened1835
AS, LTFU (EOT + 9 months) — Stable5886
AS, LTFU (EOT + 9 months) — Improved3159
PN, LTFU (EOT + 9 months) — Worsened6092
PN, LTFU (EOT + 9 months) — Stable2447
PN, LTFU (EOT + 9 months) — Improved2341
MS, LTFU (EOT + 9 months) — Worsened2238
MS, LTFU (EOT + 9 months) — Stable5082
MS, LTFU (EOT + 9 months) — Improved3560
CSE, LTFU (EOT + 9 months) — Worsened3248
CSE, LTFU (EOT + 9 months) — Stable5488
CSE, LTFU (EOT + 9 months) — Improved2144
HS, LTFU (EOT + 9 months) — Worsened1216
HS, LTFU (EOT + 9 months) — Stable2640
HS, LTFU (EOT + 9 months) — Improved69123
BI, LTFU (EOT + 15 months) — Worsened2242
BI, LTFU (EOT + 15 months) — Stable3146
BI, LTFU (EOT + 15 months) — Improved2361
S, LTFU (EOT + 15 months) — Worsened1226
S, LTFU (EOT + 15 months) — Stable4386
S, LTFU (EOT + 15 months) — Improved1531
ATD, LTFU (EOT + 15 months) — Worsened3054
ATD, LTFU (EOT + 15 months) — Stable1633
ATD, LTFU (EOT + 15 months) — Improved3061
AS, LTFU (EOT + 15 months) — Worsened1923
AS, LTFU (EOT + 15 months) — Stable3781
AS, LTFU (EOT + 15 months) — Improved2045
PN, LTFU (EOT + 15 months) — Worsened4379
PN, LTFU (EOT + 15 months) — Stable1340
PN, LTFU (EOT + 15 months) — Improved2027
MS, LTFU (EOT + 15 months) — Worsened1737
MS, LTFU (EOT + 15 months) — Stable4178
MS, LTFU (EOT + 15 months) — Improved1834
CSE, LTFU (EOT + 15 months) — Worsened1945
CSE, LTFU (EOT + 15 months) — Stable4173
CSE, LTFU (EOT + 15 months) — Improved1629
HS, LTFU (EOT + 15 months) — Worsened713
HS, LTFU (EOT + 15 months) — Stable2134
HS, LTFU (EOT + 15 months) — Improved48101
BI, LTFU (EOT + 21 months) — Worsened1226
BI, LTFU (EOT + 21 months) — Stable1831
BI, LTFU (EOT + 21 months) — Improved1639
S, LTFU (EOT + 21 months) — Worsened513
S, LTFU (EOT + 21 months) — Stable2662
S, LTFU (EOT + 21 months) — Improved1318
ATD, LTFU (EOT + 21 months) — Worsened1736
ATD, LTFU (EOT + 21 months) — Stable1118
ATD, LTFU (EOT + 21 months) — Improved1842
AS, LTFU (EOT + 21 months) — Worsened1219
AS, LTFU (EOT + 21 months) — Stable2548
AS, LTFU (EOT + 21 months) — Improved1029
PN, LTFU (EOT + 21 months) — Worsened1853
PN, LTFU (EOT + 21 months) — Stable1325
PN, LTFU (EOT + 21 months) — Improved1518
MS, LTFU (EOT + 21 months) — Worsened1225
MS, LTFU (EOT + 21 months) — Stable2144
MS, LTFU (EOT + 21 months) — Improved1427
CSE, LTFU (EOT + 21 months) — Worsened1025
CSE, LTFU (EOT + 21 months) — Stable2750
CSE, LTFU (EOT + 21 months) — Improved921
HS, LTFU (EOT + 21 months) — Worsened411
HS, LTFU (EOT + 21 months) — Stable622
HS, LTFU (EOT + 21 months) — Improved3762
BI, LTFU (EOT + 27 months) — Worsened1021
BI, LTFU (EOT + 27 months) — Stable1522
BI, LTFU (EOT + 27 months) — Improved1026
S, LTFU (EOT + 27 months) — Worsened69
S, LTFU (EOT + 27 months) — Stable1841
S, LTFU (EOT + 27 months) — Improved816
ATD, LTFU (EOT + 27 months) — Worsened1628
ATD, LTFU (EOT + 27 months) — Stable714
ATD, LTFU (EOT + 27 months) — Improved1127
AS, LTFU (EOT + 27 months) — Worsened515
AS, LTFU (EOT + 27 months) — Stable2138
AS, LTFU (EOT + 27 months) — Improved916
PN, LTFU (EOT + 27 months) — Worsened1936
PN, LTFU (EOT + 27 months) — Stable916
PN, LTFU (EOT + 27 months) — Improved717
MS, LTFU (EOT + 27 months) — Worsened817
MS, LTFU (EOT + 27 months) — Stable1829
MS, LTFU (EOT + 27 months) — Improved923
CSE, LTFU (EOT + 27 months) — Worsened1124
CSE, LTFU (EOT + 27 months) — Stable1831
CSE, LTFU (EOT + 27 months) — Improved614
HS, LTFU (EOT + 27 months) — Worsened68
HS, LTFU (EOT + 27 months) — Stable714
HS, LTFU (EOT + 27 months) — Improved2247
BI, LTFU (EOT + 33 months) — Worsened112
BI, LTFU (EOT + 33 months) — Stable812
BI, LTFU (EOT + 33 months) — Improved715
S, LTFU (EOT + 33 months) — Worsened06
S, LTFU (EOT + 33 months) — Stable1323
S, LTFU (EOT + 33 months) — Improved39
ATD, LTFU (EOT + 33 months) — Worsened915
ATD, LTFU (EOT + 33 months) — Stable46
ATD, LTFU (EOT + 33 months) — Improved318
AS, LTFU (EOT + 33 months) — Worsened47
AS, LTFU (EOT + 33 months) — Stable725
AS, LTFU (EOT + 33 months) — Improved57
PN, LTFU (EOT + 33 months) — Worsened819
PN, LTFU (EOT + 33 months) — Stable512
PN, LTFU (EOT + 33 months) — Improved28
MS, LTFU (EOT + 33 months) — Worsened212
MS, LTFU (EOT + 33 months) — Stable817
MS, LTFU (EOT + 33 months) — Improved610
CSE, LTFU (EOT + 33 months) — Worsened411
CSE, LTFU (EOT + 33 months) — Stable720
CSE, LTFU (EOT + 33 months) — Improved48
HS, LTFU (EOT + 33 months) — Worsened15
HS, LTFU (EOT + 33 months) — Stable311
HS, LTFU (EOT + 33 months) — Improved1123
BI, LTFU (EOT + 39 months) — Worsened311
BI, LTFU (EOT + 39 months) — Stable66
BI, LTFU (EOT + 39 months) — Improved210
S, LTFU (EOT + 39 months) — Worsened06
S, LTFU (EOT + 39 months) — Stable1018
S, LTFU (EOT + 39 months) — Improved13
ATD, LTFU (EOT + 39 months) — Worsened312
ATD, LTFU (EOT + 39 months) — Stable35
ATD, LTFU (EOT + 39 months) — Improved510
AS, LTFU (EOT + 39 months) — Worsened25
AS, LTFU (EOT + 39 months) — Stable618
AS, LTFU (EOT + 39 months) — Improved34
PN, LTFU (EOT + 39 months) — Worsened514
PN, LTFU (EOT + 39 months) — Stable48
PN, LTFU (EOT + 39 months) — Improved25
MS, LTFU (EOT + 39 months) — Worsened410
MS, LTFU (EOT + 39 months) — Stable610
MS, LTFU (EOT + 39 months) — Improved17
CSE, LTFU (EOT + 39 months) — Worsened38
CSE, LTFU (EOT + 39 months) — Stable714
CSE, LTFU (EOT + 39 months) — Improved15
HS, LTFU (EOT + 39 months) — Worsened13
HS, LTFU (EOT + 39 months) — Stable35
HS, LTFU (EOT + 39 months) — Improved719
BI, LTFU (EOT + 45 months) — Worsened16
BI, LTFU (EOT + 45 months) — Stable25
BI, LTFU (EOT + 45 months) — Improved15
S, LTFU (EOT + 45 months) — Worsened11
S, LTFU (EOT + 45 months) — Stable311
S, LTFU (EOT + 45 months) — Improved03
ATD, LTFU (EOT + 45 months) — Worsened35
ATD, LTFU (EOT + 45 months) — Stable05
ATD, LTFU (EOT + 45 months) — Improved16
AS, LTFU (EOT + 45 months) — Worsened04
AS, LTFU (EOT + 45 months) — Stable210
AS, LTFU (EOT + 45 months) — Improved22
PN, LTFU (EOT + 45 months) — Worsened311
PN, LTFU (EOT + 45 months) — Stable04
PN, LTFU (EOT + 45 months) — Improved11
MS, LTFU (EOT + 45 months) — Worsened06
MS, LTFU (EOT + 45 months) — Stable35
MS, LTFU (EOT + 45 months) — Improved15
CSE, LTFU (EOT + 45 months) — Worsened15
CSE, LTFU (EOT + 45 months) — Stable210
CSE, LTFU (EOT + 45 months) — Improved11
HS, LTFU (EOT + 45 months) — Worsened01
HS, LTFU (EOT + 45 months) — Stable33
HS, LTFU (EOT + 45 months) — Improved112
BI, LTFU (EOT + 51 months) — Worsened11
BI, LTFU (EOT + 51 months) — Stable11
BI, LTFU (EOT + 51 months) — Improved03
S, LTFU (EOT + 51 months) — Worsened10
S, LTFU (EOT + 51 months) — Stable04
S, LTFU (EOT + 51 months) — Improved01
ATD, LTFU (EOT + 51 months) — Worsened21
ATD, LTFU (EOT + 51 months) — Stable02
ATD, LTFU (EOT + 51 months) — Improved02
AS, LTFU (EOT + 51 months) — Worsened00
AS, LTFU (EOT + 51 months) — Stable25
AS, LTFU (EOT + 51 months) — Improved00
PN, LTFU (EOT + 51 months) — Worsened22
PN, LTFU (EOT + 51 months) — Stable02
PN, LTFU (EOT + 51 months) — Improved01
MS, LTFU (EOT + 51 months) — Worsened01
MS, LTFU (EOT + 51 months) — Stable23
MS, LTFU (EOT + 51 months) — Improved01
CSE, LTFU (EOT + 51 months) — Worsened02
CSE, LTFU (EOT + 51 months) — Stable13
CSE, LTFU (EOT + 51 months) — Improved10
HS, LTFU (EOT + 51 months) — Worsened00
HS, LTFU (EOT + 51 months) — Stable12
HS, LTFU (EOT + 51 months) — Improved13
BI, LTFU (EOT + 57 months) — Worsened00
BI, LTFU (EOT + 57 months) — Stable10
BI, LTFU (EOT + 57 months) — Improved11
S, LTFU (EOT + 57 months) — Worsened10
S, LTFU (EOT + 57 months) — Stable01
S, LTFU (EOT + 57 months) — Improved00
ATD, LTFU (EOT + 57 months) — Worsened00
ATD, LTFU (EOT + 57 months) — Stable21
ATD, LTFU (EOT + 57 months) — Improved00
AS, LTFU (EOT + 57 months) — Worsened00
AS, LTFU (EOT + 57 months) — Stable21
AS, LTFU (EOT + 57 months) — Improved00
PN, LTFU (EOT + 57 months) — Worsened21
PN, LTFU (EOT + 57 months) — Stable00
PN, LTFU (EOT + 57 months) — Improved00
MS, LTFU (EOT + 57 months) — Worsened00
MS, LTFU (EOT + 57 months) — Stable20
MS, LTFU (EOT + 57 months) — Improved01
CSE, LTFU (EOT + 57 months) — Worsened10
CSE, LTFU (EOT + 57 months) — Stable01
CSE, LTFU (EOT + 57 months) — Improved10
HS, LTFU (EOT + 57 months) — Worsened00
HS, LTFU (EOT + 57 months) — Stable01
HS, LTFU (EOT + 57 months) — Improved10
BI, LTFU (EOT + 63 months) — Worsened00
BI, LTFU (EOT + 63 months) — Stable10
BI, LTFU (EOT + 63 months) — Improved00
S, LTFU (EOT + 63 months) — Worsened10
S, LTFU (EOT + 63 months) — Stable00
S, LTFU (EOT + 63 months) — Improved00
ATD, LTFU (EOT + 63 months) — Worsened00
ATD, LTFU (EOT + 63 months) — Stable10
ATD, LTFU (EOT + 63 months) — Improved00
AS, LTFU (EOT + 63 months) — Worsened00
AS, LTFU (EOT + 63 months) — Stable10
AS, LTFU (EOT + 63 months) — Improved00
PN, LTFU (EOT + 63 months) — Worsened10
PN, LTFU (EOT + 63 months) — Stable00
PN, LTFU (EOT + 63 months) — Improved00
MS, LTFU (EOT + 63 months) — Worsened00
MS, LTFU (EOT + 63 months) — Stable10
MS, LTFU (EOT + 63 months) — Improved00
CSE, LTFU (EOT + 63 months) — Worsened00
CSE, LTFU (EOT + 63 months) — Stable00
CSE, LTFU (EOT + 63 months) — Improved10
HS, LTFU (EOT + 63 months) — Worsened00
HS, LTFU (EOT + 63 months) — Stable00
HS, LTFU (EOT + 63 months) — Improved10

Adverse events

Collected over All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Not Treated33/79 (41.8%)35/79 (44.3%)51/79 (64.6%)
Paclitaxel + Carboplatin + Dostarlimab Pbo +/- Bev, Then Niraparib Pbo+Dostarlimab Pbo +/-Bev (Arm1)106/159 (66.7%)63/159 (39.6%)158/159 (99.4%)
Paclitaxel + Carboplatin + Dostarlimab Pbo +/- Bev, Then Niraparib+Dostarlimab Pbo +/- Bev (Arm2)235/417 (56.4%)190/417 (45.6%)417/417 (100%)
Paclitaxel + Carboplatin + Dostarlimab +/- Bev, Then Niraparib+Dostarlimab +/- Bev (Arm3)430/745 (57.7%)405/745 (54.4%)745/745 (100%)
Most frequent serious events
Showing 10 of 394
Most frequent serious events
EventNot TreatedPaclitaxel + Carboplatin + Dostarlimab Pbo +/- Bev, Then Niraparib Pbo+Dostarlimab Pbo +/-Bev (Arm1)Paclitaxel + Carboplatin + Dostarlimab Pbo +/- Bev, Then Niraparib+Dostarlimab Pbo +/- Bev (Arm2)Paclitaxel + Carboplatin + Dostarlimab +/- Bev, Then Niraparib+Dostarlimab +/- Bev (Arm3)
ThrombocytopeniaBlood and lymphatic system disorders0/792/15925/41731/745
AnaemiaBlood and lymphatic system disorders0/793/15919/41728/745
Intestinal obstructionGastrointestinal disorders3/793/15911/41717/745
Abdominal painGastrointestinal disorders2/796/15910/41725/745
Platelet count decreasedInvestigations1/791/15910/41728/745
Small intestinal obstructionGastrointestinal disorders1/794/15912/41721/745
PyrexiaGeneral disorders0/794/1592/41721/745
Febrile neutropeniaBlood and lymphatic system disorders2/792/1596/41720/745
VomitingGastrointestinal disorders2/791/1594/4179/745
SubileusGastrointestinal disorders2/790/1592/4173/745
Most frequent other events
Showing 10 of 84
Most frequent other events
EventNot TreatedPaclitaxel + Carboplatin + Dostarlimab Pbo +/- Bev, Then Niraparib Pbo+Dostarlimab Pbo +/-Bev (Arm1)Paclitaxel + Carboplatin + Dostarlimab Pbo +/- Bev, Then Niraparib+Dostarlimab Pbo +/- Bev (Arm2)Paclitaxel + Carboplatin + Dostarlimab +/- Bev, Then Niraparib+Dostarlimab +/- Bev (Arm3)
AnaemiaBlood and lymphatic system disorders11/7970/159269/417485/745
NauseaGastrointestinal disorders15/7986/159251/417443/745
ConstipationGastrointestinal disorders7/7970/159193/417365/745
Neuropathy peripheralNervous system disorders1/7976/159173/417312/745
FatigueGeneral disorders6/7961/159151/417346/745
AlopeciaSkin and subcutaneous tissue disorders4/7966/159193/417328/745
ArthralgiaMusculoskeletal and connective tissue disorders1/7964/159155/417293/745
DiarrhoeaGastrointestinal disorders11/7963/159148/417296/745
ThrombocytopeniaBlood and lymphatic system disorders3/7922/159164/417263/745
AstheniaGeneral disorders8/7953/159158/417254/745

Baseline characteristics

All eligible enrolled participants received SOC during the Cycle 1 Chemotherapy Run-In Period before randomization.

Age, Continuous
Age, Continuous(YEARS)All Enrolled Participants
Mean62.0 ± 10.81
Sex: Female, Male
Sex: Female, Male(Participants)All Enrolled Participants
Female1400
Male0
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)All Enrolled Participants
White1245
Black or African American30
Asian29
American Indian or Alaska Native8
Unknown80
Not Reported8
08

Study locations

182 sites
  • GSK Investigational Site
    Anchorage, Alaska 99508, United States
  • GSK Investigational Site
    Phoenix, Arizona 85016, United States
  • GSK Investigational Site
    Tucson, Arizona 85711, United States
  • GSK Investigational Site
    Los Angeles, California 90027, United States
  • GSK Investigational Site
    Los Angeles, California 90048, United States
  • GSK Investigational Site
    Newport Beach, California 92663, United States
  • GSK Investigational Site
    Farmington, Connecticut 06030, United States
  • GSK Investigational Site
    Hartford, Connecticut 06102, United States
  • GSK Investigational Site
    Gainesville, Florida 32608, United States
  • GSK Investigational Site
    Jacksonville, Florida 32256, United States
  • GSK Investigational Site
    Geneva, Illinois 60555, United States
  • GSK Investigational Site
    Warrenville, Illinois 60555, United States
  • GSK Investigational Site
    Zion, Illinois 60099, United States
  • GSK Investigational Site
    Covington, Louisiana 70433, United States
  • GSK Investigational Site
    New Orleans, Louisiana 70121, United States
  • GSK Investigational Site
    Shreveport, Louisiana 71103, United States
  • GSK Investigational Site
    Scarborough, Maine 04074, United States
  • GSK Investigational Site
    Baltimore, Maryland 21201, United States
  • GSK Investigational Site
    Silver Spring, Maryland 20910, United States
  • GSK Investigational Site
    Boston, Massachusetts 02215, United States
  • GSK Investigational Site
    Springfield, Massachusetts 01199, United States
  • GSK Investigational Site
    Worcester, Massachusetts 01605, United States
  • GSK Investigational Site
    Minneapolis, Minnesota 55404, United States
  • GSK Investigational Site
    Minneapolis, Minnesota 55455, United States
  • GSK Investigational Site
    Billings, Montana 59101, United States
  • GSK Investigational Site
    Neptune City, New Jersey 07753, United States
  • GSK Investigational Site
    Teaneck, New Jersey 07666, United States
  • GSK Investigational Site
    Hawthorne, New York 10532, United States
  • GSK Investigational Site
    New York, New York 10016, United States
  • GSK Investigational Site
    New York, New York 10029, United States
  • GSK Investigational Site
    New York, New York 10065, United States
  • GSK Investigational Site
    Rochester, New York 14620-4159, United States
  • GSK Investigational Site
    Stony Brook, New York 11794, United States
  • GSK Investigational Site
    Syracuse, New York 13210, United States
  • GSK Investigational Site
    Charlotte, North Carolina 28204, United States
  • GSK Investigational Site
    Canton, Ohio 44710, United States
  • GSK Investigational Site
    Cincinnati, Ohio 45219, United States
  • GSK Investigational Site
    Oklahoma City, Oklahoma 73104, United States
  • GSK Investigational Site
    Eugene, Oregon 97401, United States
  • GSK Investigational Site
    Portland, Oregon 97227, United States
  • GSK Investigational Site
    Paoli, Pennsylvania 19301, United States
  • GSK Investigational Site
    Philadelphia, Pennsylvania 19111, United States
  • GSK Investigational Site
    Pittsburgh, Pennsylvania 15224, United States
  • GSK Investigational Site
    Pittsburgh, Pennsylvania 15232, United States
  • GSK Investigational Site
    Willow Grove, Pennsylvania 19001-3788, United States
  • GSK Investigational Site
    Wynnewood, Pennsylvania 19096, United States
  • GSK Investigational Site
    Providence, Rhode Island 02905, United States
  • GSK Investigational Site
    Charleston, South Carolina 29425, United States
  • GSK Investigational Site
    Sioux Falls, South Dakota 57105, United States
  • GSK Investigational Site
    Knoxville, Tennessee 37920, United States
  • GSK Investigational Site
    Nashville, Tennessee 37203, United States
  • GSK Investigational Site
    Nashville, Tennessee 37205, United States
  • GSK Investigational Site
    Austin, Texas 78731, United States
  • GSK Investigational Site
    Dallas, Texas 75246, United States
  • GSK Investigational Site
    Fort Worth, Texas 76104, United States
  • GSK Investigational Site
    Houston, Texas 77030, United States
  • GSK Investigational Site
    San Antonio, Texas 78240, United States
  • GSK Investigational Site
    The Woodlands, Texas 77380, United States
  • GSK Investigational Site
    Tyler, Texas 75702, United States
  • GSK Investigational Site
    Ogden, Utah 84405, United States
  • GSK Investigational Site
    Charlottesville, Virginia 22903, United States
  • GSK Investigational Site
    Norfolk, Virginia 23502, United States
  • GSK Investigational Site
    Kennewick, Washington 99336, United States
  • GSK Investigational Site
    Seattle, Washington 98104, United States
  • GSK Investigational Site
    Seattle, Washington 98109, United States
  • GSK Investigational Site
    Minsk, 223040, Belarus
  • GSK Investigational Site
    Brasschaat, 2930, Belgium
  • GSK Investigational Site
    Bruges, 8000, Belgium
  • GSK Investigational Site
    Vancouver, British Columbia V5Z 4E6, Canada
  • GSK Investigational Site
    London, Ontario N6A 4L6, Canada
  • GSK Investigational Site
    Toronto, Ontario M4N 3M5, Canada
  • GSK Investigational Site
    Montreal, Quebec H2X 3E4, Canada
  • GSK Investigational Site
    Montreal, Quebec H4A 3J1, Canada
  • GSK Investigational Site
    Sherbrooke, Quebec J1H 5N4, Canada
  • GSK Investigational Site
    Windsor, 1000, Canada
  • GSK Investigational Site
    Prague, 128 51, Czechia
  • GSK Investigational Site
    Prague, 180 81, Czechia
  • GSK Investigational Site
    Copenhagen, DK- 2100, Denmark
  • GSK Investigational Site
    Herlev, 2730, Denmark
  • GSK Investigational Site
    Roskilde, 4000, Denmark
  • GSK Investigational Site
    Helsinki, 00029, Finland
  • GSK Investigational Site
    Kuopio, 70210, Finland
  • GSK Investigational Site
    Tampere, 33520, Finland
  • GSK Investigational Site
    Turku, 20520, Finland
  • GSK Investigational Site
    Angers, 49055, France
  • GSK Investigational Site
    Avignon, 84918, France
  • GSK Investigational Site
    Besançon, 25030, France
  • GSK Investigational Site
    Bordeaux, 33000, France
  • GSK Investigational Site
    Bron, 69495, France
  • GSK Investigational Site
    Caen, 14000, France
  • GSK Investigational Site
    Cholet, 69373, France
  • GSK Investigational Site
    Clermont-Ferrand, 63011, France
  • GSK Investigational Site
    Dijon, 21079, France
  • GSK Investigational Site
    Grenoble, 38000, France
  • GSK Investigational Site
    Grenoble, 38700, France
  • GSK Investigational Site
    Le Mans, 72000, France
  • GSK Investigational Site
    Lille, 59000, France
  • GSK Investigational Site
    Lyon, 69008, France
  • GSK Investigational Site
    Lyon, 69373, France
  • GSK Investigational Site
    Lyon, 69495, France

Showing the first 100 of 182 sites across 19 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — GSK will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/About_GSK_Patient_Level_Data_Sharing_Final_13July2023.pdf.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2018 to primary completion in Oct 2024, 72 months.

Results were first posted in Dec 2025, 1 year 2 months after primary completion.

Of 73 industry-sponsored phase 3 interventional studies under Ovarian Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 72. This study's 72 months is above that.

Counting every sponsor, half of 125 studies reached it within 59 months; a quarter within 37 and three quarters within 89.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 28, 2018
First posted
Jul 27, 2018
StartActual
Oct 11, 2018
Primary completionActual
Oct 31, 2024
CompletionEst.
Apr 30, 2029
Results first posted
Dec 31, 2025
Last update
Dec 31, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 31, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03602859
Lead sponsor
Tesaro, Inc.
Collaborators
European Network of Gynaecological Oncological Trial Groups (ENGOT)
Responsible party
Sponsor
First posted
Jul 27, 2018
Start date
Oct 11, 2018
Primary completion
Oct 31, 2024
Completion
Apr 30, 2029 (estimated)
Results posted
Dec 31, 2025
Last update
Dec 31, 2025

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Niraparib · Dostarlimab

Start the discussion